var title_f31_20_32064="Tinel test carpal tunnel";
var content_f31_20_32064=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F58010&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F58010&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    The Hoffman-Tinel test",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 426px; height: 284px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a patient with the carpal tunnel syndrome, tapping over a compressed nerve at the wrist reproduces pain and paresthesia, proximal or distal to the site of compression.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Sheon, RP, Moskowitz, RW, Goldberg, VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd ed, Williams &amp; Wilkins, Baltimore 1996.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_20_32064=[""].join("\n");
var outline_f31_20_32064=null;
var title_f31_20_32065="Patient information: Turner syndrome (The Basics)";
var content_f31_20_32065=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?3/12/3266\">",
"         Patient information: My child is short (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?30/1/30738\">",
"         Patient information: Normal sexual development (puberty) (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?39/62/40932\">",
"         Patient information: In vitro fertilization (IVF) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Turner syndrome (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H92375081\">",
"      <span class=\"h1\">",
"       What is Turner syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Turner syndrome is a genetic problem that affects only girls. It keeps a girl from growing normally and from developing normal ovaries. It can also cause problems with the kidneys, heart, and other organs.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H92375096\">",
"      <span class=\"h1\">",
"       What are the symptoms of Turner syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Girls with Turner syndrome can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Be short",
"       </li>",
"       <li>",
"        Have a square-shaped chest",
"       </li>",
"       <li>",
"        Be born with swollen or puffy hands and feet",
"       </li>",
"       <li>",
"        Have a webbed neck",
"       </li>",
"       <li>",
"        Have nipples that are far apart",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Girls with Turner syndrome do not have normal ovaries so they do not go through puberty on their own. That means they do not form breasts or have periods unless they are treated with female hormones. They also do not grow as much as they should unless they take growth hormone shots.",
"     </p>",
"     <p>",
"      Girls with Turner syndrome are usually as smart as those without the condition, but they can have trouble with certain types of mental tasks. They can also have other problems, including:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Heart problems",
"       </li>",
"       <li>",
"        Kidney or liver problems",
"       </li>",
"       <li>",
"        Thyroid disease",
"       </li>",
"       <li>",
"        Hearing loss and ear infections",
"       </li>",
"       <li>",
"        Eye problems",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H92375111\">",
"      <span class=\"h1\">",
"       Is there a test for Turner syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If a doctor or nurse thinks a child might have Turner syndrome, he or she can order a blood test to look for the genetic problem that causes it.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H92375126\">",
"      <span class=\"h1\">",
"       How is Turner syndrome treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There is no way to cure Turner syndrome, but there are ways to reduce the problems it causes. Girls can be treated with hormones to help them grow to a normal height and to go through the changes that normally happen at puberty. At various points throughout their lives, they must also be checked for the problems that Turner syndrome can cause. This involves hearing tests, many different blood tests, and some tests to check the condition of the heart. If any of those problems happen, they must get treated for those as well.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H92375141\">",
"      <span class=\"h1\">",
"       What if my daughter wants to have children?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Even with treatment, many girls with Turner syndrome can&rsquo;t have children when they grow up. Some can get pregnant with a special treatment called &ldquo;in-vitro fertilization,&rdquo; which uses another woman&rsquo;s eggs. If your daughter wants to have children, when she is ready, she should ask her doctor what her options are.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H92375156\">",
"      <span class=\"h1\">",
"       What will my child&rsquo;s life be like?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Girls with Turner syndrome need special medical attention all of their lives. But very few girls with Turner syndrome get the medical care they need when they are adults. When your child grows up, make sure she understands that she should keep getting check-ups every year. The doctor should check her for signs of:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Heart problems",
"       </li>",
"       <li>",
"        Thyroid disease",
"       </li>",
"       <li>",
"        Diabetes",
"       </li>",
"       <li>",
"        High cholesterol",
"       </li>",
"       <li>",
"        Liver problems",
"       </li>",
"       <li>",
"        Hearing loss",
"       </li>",
"       <li>",
"        Eye problems",
"       </li>",
"       <li>",
"        Osteoporosis (a condition that weakens bones)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      The Turner Syndrome Society of the United States has more information on the types of care people with Turner syndrome need. They can be reached at 1-800-365-9944 or",
"      <a class=\"external\" href=\"file://www.turnersyndrome.org/\">",
"       www.turnersyndrome.org",
"      </a>",
"      .",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H92375171\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/12/3266?source=see_link\">",
"       Patient information: My child is short (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/1/30738?source=see_link\">",
"       Patient information: Normal sexual development (puberty) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/62/40932?source=see_link\">",
"       Patient information: In vitro fertilization (IVF) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?31/20/32065?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86453 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.122.249.114-59E8FFCE15-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_20_32065=[""].join("\n");
var outline_f31_20_32065=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H92375081\">",
"      What is Turner syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H92375096\">",
"      What are the symptoms of Turner syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H92375111\">",
"      Is there a test for Turner syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H92375126\">",
"      How is Turner syndrome treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H92375141\">",
"      What if my daughter wants to have children?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H92375156\">",
"      What will my child&rsquo;s life be like?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H92375171\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/62/40932?source=related_link\">",
"      Patient information: In vitro fertilization (IVF) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/12/3266?source=related_link\">",
"      Patient information: My child is short (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/1/30738?source=related_link\">",
"      Patient information: Normal sexual development (puberty) (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_20_32066="Pelvic fractures";
var content_f31_20_32066=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F76038&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F76038&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Pelvic fractures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 167px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Rotationally unstable fracture. The symphysis pubis is separated and the anterior sacroiliac, sacrotuberous, and sacrospinous ligaments are disrupted.",
"    <br>",
"     (B) Vertically unstable fracture. The hemipelvis is displaced anteriorly and posteriorly through the symphysis pubis, and the sacroiliac joint ligaments are disrupted.",
"     <br>",
"      (C) Non-displaced fracture of the acetabulum.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Reproduced with permission from: Smeltzer S, Bare B. Brunner and Suddarth's Textbook of Medical-Surgical Nursing, Ninth Edition. Philadelphia: Lippincott Williams &amp; Wilkins. Copyright &copy; 2000 Lippincott Williams &amp; Wilkins.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_20_32066=[""].join("\n");
var outline_f31_20_32066=null;
var title_f31_20_32067="Brompheniramine and phenylephrine: Drug information";
var content_f31_20_32067=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Brompheniramine and phenylephrine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?6/3/6197?source=see_link\">",
"    see \"Brompheniramine and phenylephrine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7675109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      BroveX&trade; PEB [OTC];",
"     </li>",
"     <li>",
"      Dimaphen&trade; Children's Cold &amp; Allergy [OTC];",
"     </li>",
"     <li>",
"      Dimetapp&reg; Children's Cold &amp; Allergy [OTC];",
"     </li>",
"     <li>",
"      Entre-B [OTC];",
"     </li>",
"     <li>",
"      LoHist PEB [OTC];",
"     </li>",
"     <li>",
"      Rynex PE;",
"     </li>",
"     <li>",
"      Vazobid-PD&trade; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F7675112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alkylamine Derivative;",
"     </li>",
"     <li>",
"      Alpha-Adrenergic Agonist;",
"     </li>",
"     <li>",
"      Decongestant;",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist",
"     </li>",
"     <li>",
"      Histamine H",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist, First Generation",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F7677174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Antihistamine/decongestant:",
"     </b>",
"     Oral: Liquid:",
"     <b>",
"      Note:",
"     </b>",
"     All dosing is presented in terms of brompheniramine maleate and phenylephrine hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brompheniramine 1 mg and phenylephrine 2.5 mg per 5 mL: 20 mL every 4-6 hours (maximum: 120 mL/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brompheniramine 1.2 mg and phenylephrine 2 mg",
"     <b>",
"      per 1 mL",
"     </b>",
"     : 3 mL every 4-6 hours (maximum: 18 mL/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brompheniramine 4 mg and phenylephrine 10 mg per 5 mL: 5 mL every 4-6 hours; (maximum: 30 mL/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brompheniramine 6 mg and phenylephrine 10 mg per 5 mL: 5 mL every 6 hours (maximum: 20 mL/24 hours)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F7677173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Antihistamine/decongestant:",
"     </b>",
"     Oral: Liquid:",
"     <b>",
"      Note:",
"     </b>",
"     All dosing is presented in terms of brompheniramine maleate and phenylephrine hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children 2-5 years: Brompheniramine 1 mg and phenylephrine 2.5 mg per 5 mL: 5 mL every 4 hours (maximum: 30 mL/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children 6-11 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Brompheniramine 1 mg and phenylephrine 2.5 mg per 5 mL: 10 mL every 4-6 hours (maximum: 60 mL/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Brompheniramine 1.2 mg and phenylephrine 2 mg",
"     <b>",
"      per 1 mL",
"     </b>",
"     : 1.5 mL every 4-6 hours (maximum: 9 mL/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Brompheniramine 4 mg and phenylephrine 10 mg per 5 mL: 2.5 mL every 4-6 hours (maximum: 15 mL/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F7677823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F239199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elixir, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dimaphen&trade; Children's Cold &amp; Allergy: Brompheniramine maleate 1 mg and phenylephrine hydrochloride 2.5 mg per 5 mL (118 mL, 237 mL) [ethanol free, gluten free; contains propylene glycol, sodium 2 mg/5 mL, sodium benzoate; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     BroveX&trade; PEB: Brompheniramine maleate 4 mg and phenylephrine hydrochloride 10 mg per 5 mL (473 mL) [dye free, ethanol free, gluten free, sugar free; contains propylene glycol; bubblegum flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dimetapp&reg; Children&rsquo;s Cold &amp; Allergy: Brompheniramine maleate 1 mg and phenylephrine hydrochloride 2.5 mg per 5 mL (118 mL, 237 mL) [ethanol free; contains sodium 3 mg/5 mL, propylene glycol, sodium benzoate; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LoHist PEB: Brompheniramine maleate 4 mg and phenylephrine hydrochloride 10 mg per 5 mL (118 mL, 473 mL) [dye free, ethanol free, sugar free; contains propylene glycol, sodium benzoate; bubble gum flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rynex PE: Brompheniramine maleate 1 mg and phenylephrine hydrochloride 2.5 mg per 5 mL (473 mL) [ethanol free, gluten free, sugar free; contains propylene glycol; bubblegum flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Entre-B: Brompheniramine maleate 6 mg and phenylephrine hydrochloride 10 mg per 5 mL (118 mL) [contains benzoic acid, propylene glycol; bubble gum flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vazobid-PD&trade;: Brompheniramine maleate 1.2 mg and phenylephrine hydrochloride 2 mg per 1 mL (118 mL) [contains aspartame, sodium benzoate; bubblegum flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F7675111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F7677176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Shake suspension well before use.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F239200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Temporary relief of upper respiratory conditions such as nasal congestion, runny nose, itchy/watery eyes, and sneezing due to the common cold, hay fever, or upper respiratory allergies",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F7677164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F239202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to brompheniramine, phenylephrine, or any component of the formulation; use with or within 14 days of MAO inhibitor therapy; do not use to sedate a child; newborns; breast-feeding",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Additional contraindications per some manufacturers: Severe CAD, severe hypertension; narrow angle glaucoma; urinary retention; peptic ulcer; acute asthma attack",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F239193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (including hypertension).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased intraocular pressure/glaucoma: Use with caution in patients with increased intraocular pressure or glaucoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary obstruction: Use with caution in patients with prostatic hyperplasia and/or GU obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pyloroduodenal obstruction: Use with caution in patients with pyloroduodenal obstruction (including stenotic peptic ulcer).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with asthma or other chronic breathing disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Antihistamines may cause excitation in young children. Do not exceed pediatric dosing recommendations. If no recommendations exist on OTC labeling for patient&rsquo;s age, the product should",
"     <b>",
"      not",
"     </b>",
"     be administered without the guidance of a physician.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Self-medication (OTC use): When used for self medication (OTC), notify healthcare provider if symptoms do not improve within 7 days or are accompanied by fever. Discontinue and contact healthcare provider if nervousness, dizziness, or sleeplessness occur.",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F7677167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: May increase CNS depression. Management: Monitor for increased effects with coadministration; caution patients about effect.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F7677175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products contain sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16324138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Dimetapp Cold/Allergy Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-2.5 mg (20): $4.97",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Elixir",
"     </b>",
"     (Dimetapp Cold/Allergy Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-2.5 mg/5 mL (118 mL): $5.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (BroveX PEB Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-10 mg/5 mL (473 mL): $193.09",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Dimetapp DM Cold/Cough Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5-1-5 mg/5 mL (118 mL): $5.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Vazobid-PD Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6-10 mg/5 mL (118 mL): $40.77",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F7677170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9070 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.167.4.114-3ADB073D65-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_20_32067=[""].join("\n");
var outline_f31_20_32067=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7675109\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7675112\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7677174\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7677173\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7677823\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F239199\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7675111\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7677176\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F239200\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7677164\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F239202\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F239193\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7677167\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7677175\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16324138\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7677170\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9070\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9070|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?6/3/6197?source=related_link\">",
"      Brompheniramine and phenylephrine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_20_32068="Ulnar collateral ligament injury (gamekeeper's or skier's thumb)";
var content_f31_20_32068=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Ulnar collateral ligament injury (gamekeeper's or skier's thumb)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/20/32068/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/20/32068/contributors\">",
"     Bruce C Anderson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/20/32068/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/20/32068/contributors\">",
"     Patrice Eiff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/20/32068/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/20/32068/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?31/20/32068/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gamekeeper's thumb (or skier's thumb) derives its name from court gamekeepers who developed chronic degeneration of the ulnar collateral ligament of the metacarpophalangeal (MP) joint when twisting the necks of fowl and other game caught while hunting. Today, ski pole injuries and other athletic injuries are the most common cause of this condition [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32068/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Thumb injuries are second in frequency only to knee injuries among skiers [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32068/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis and management of ulnar collateral ligament injury will be reviewed here. Other thumb injuries are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9928?source=see_link\">",
"     \"Evaluation of the patient with thumb pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISM OF INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Forced abduction and hyperextension of the metacarpophalangeal (MP) joint is the usual mechanism for ulnar collateral ligament (UCL) injury [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32068/abstract/1,2,4-6\">",
"     1,2,4-6",
"    </a>",
"    ]. This can occur if someone falls onto their thumb or the thumb is struck, violently forcing it into abduction. A similar mechanism occurs when a ski pole becomes fixed in the ground and the momentum of the skier drives the thumb into the pole handle. This usually occurs when a skier falls. Disruption of the ulnar collateral ligament may occur from repetitive use as well as acute injury, but this is less common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7703901\">",
"    <span class=\"h2\">",
"     Patient presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with an ulnar collateral ligament (UCL) injury complain of pain, which is exacerbated by thumb extension or abduction, and swelling along the ulnar aspect of the thumb MP joint [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32068/abstract/1,2,4-6\">",
"     1,2,4-6",
"    </a>",
"    ]. The patient often takes the thumb and first finger and rubs over the MP joint when describing the condition. If the patient presents several weeks to months after the injury, pain, weakness, or loss of stability are the usual complaints.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of UCL injury is confirmed by the following physical examination findings [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32068/abstract/1,2,4-6\">",
"     1,2,4-6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MP joint tenderness is localized to the ulnar side of the joint. The entire joint may be swollen or swelling may be localized to the ulnar side.",
"     </li>",
"     <li>",
"      Valgus stress testing reveals a loss of integrity of the UCL. This is demonstrated by increased laxity of the MP joint, particularly when compared to the uninjured thumb [",
"      <a class=\"abstract\" href=\"UTD.htm?31/20/32068/abstract/4,7\">",
"       4,7",
"      </a>",
"      ]. Note that some discrepancy in joint laxity between thumbs occurs normally in some individuals [",
"      <a class=\"abstract\" href=\"UTD.htm?31/20/32068/abstract/8\">",
"       8",
"      </a>",
"      ]. The absence of a discrete endpoint with valgus stress testing also suggests UCL injury [",
"      <a class=\"abstract\" href=\"UTD.htm?31/20/32068/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]. Valgus stress testing should be performed with the MCP joint in both neutral and flexed positions. With the MCP flexed to about 45 degrees, the UCL is isolated from other lateral stabilizers (eg, volar plate) [",
"      <a class=\"abstract\" href=\"UTD.htm?31/20/32068/abstract/10\">",
"       10",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Surgical texts commonly site an absolute increase in joint laxity of 30 degrees with valgus stress testing, or a relative increase of 15 to 20 degrees compared to the uninjured thumb, as determining UCL rupture, but in practice it can be difficult to make such measurements precisely [",
"      <a class=\"abstract\" href=\"UTD.htm?31/20/32068/abstract/9\">",
"       9",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Note that testing is performed",
"      <strong>",
"       after",
"      </strong>",
"      radiographs are obtained to rule out an avulsion fracture (",
"      <a class=\"graphic graphic_picture graphicRef53552 \" href=\"UTD.htm?35/14/36064\">",
"       picture 1",
"      </a>",
"      ). A local anesthetic block may be necessary to control the patient's pain (",
"      <a class=\"graphic graphic_picture graphicRef74150 \" href=\"UTD.htm?29/51/30527\">",
"       picture 2",
"      </a>",
"      ) and allow proper stress testing [",
"      <a class=\"abstract\" href=\"UTD.htm?31/20/32068/abstract/11\">",
"       11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/9/23703?source=see_link\">",
"       \"Digital nerve block\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The MP joint may not fully flex to 90 degrees.",
"     </li>",
"     <li>",
"      The strength or holding power (pinch grip) of the thumb and first finger may be compromised.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard posteroanterior, lateral, and oblique x-rays of the thumb are indicated in patients with suspected UCL injury to identify bony avulsions at the ligament&rsquo;s insertion at the base of the proximal phalanx (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef86891 \" href=\"UTD.htm?36/31/37361\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef86892 \" href=\"UTD.htm?35/9/35984\">",
"     image 2",
"    </a>",
"    ). In the absence of avulsion, plain films are usually normal; degenerative changes may be present years after the injury.",
"   </p>",
"   <p>",
"    If standard x-rays show no evidence of bony involvement and the thumb examination is equivocal, stress radiographs can be performed to determine the degree of UCL laxity. Ultrasonographic or fluoroscopic imaging while applying stress to the MP joint can also be useful [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32068/abstract/6,12,13\">",
"     6,12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MRI has a high sensitivity and specificity for ligament rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32068/abstract/6,14\">",
"     6,14",
"    </a>",
"    ]. In patients with evidence of complete rupture by physical examination or stress radiography, MRI can identify the relationship of the torn ulnar collateral ligament to the surrounding muscle, which may influence the need for surgery. However, an MRI is generally unnecessary [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32068/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Indications for surgical referral'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7703845\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of ulnar collateral ligament (UCL) injury is suspected on the basis of a history of thumb injury involving forced abduction, combined with suggestive examination findings, namely local signs of inflammation and laxity of the MCP joint of the thumb with valgus stress. Diagnostic imaging to rule out other bony injury and confirm laxity of the MCP joint is generally performed.",
"   </p>",
"   <p>",
"    Other causes of thumb pain are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9928?source=see_link\">",
"     \"Evaluation of the patient with thumb pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR SURGICAL REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Referral to an orthopedist or hand surgeon is indicated for patients who have a bony fragment on x-ray that is more than 2 mm displaced or involves greater than 10 to 20 percent of the articular surface, or who manifest clinical signs of a complete UCL tear (valgus testing reveals more than 30 degrees of laxity, or laxity 15 to 20 degrees greater than the uninjured thumb) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32068/abstract/15\">",
"     15",
"    </a>",
"    ]. It is best to refer the patient to a hand surgeon for more definitive evaluation if the stability of the joint appears to be compromised in any way.",
"   </p>",
"   <p>",
"    Some patients with mild joint laxity may do well with splinting initially rather than immediate surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32068/abstract/16\">",
"     16",
"    </a>",
"    ]. However, many hand surgeons consider early surgical repair the treatment of choice in these patients, particularly if the aponeurosis of the adductor pollicis becomes trapped between the ends of the torn UCL. This condition is commonly referred to as a &ldquo;Stener lesion&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32068/abstract/4,17\">",
"     4,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with normal x-rays or those showing bony fragments that are less than 2 mm displaced and minimal joint laxity with stress examination, conservative treatment may be sufficient. However, if there is any doubt about the nature or extent of a possible UCL injury, it is best to refer the patient to a specialist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     NONSURGICAL MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Acute therapy, splinting, and rehabilitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ice should be applied acutely to the MP joint. The nonsurgical treatment of choice is immobilization with a thumb spica splint (",
"    <a class=\"graphic graphic_picture graphicRef81987 \" href=\"UTD.htm?30/55/31615\">",
"     picture 3",
"    </a>",
"    ). The MP joint is typically flexed to about 20 degrees. The thumb must remain completely rested and protected for at least three weeks, after which gentle passive range of motion exercises may be performed out of the splint along with isometric strengthening of thumb flexion and intrinsic muscles of the hand (pinch and handgrip).",
"   </p>",
"   <p>",
"    Immobilization should continue for another two to three weeks when the patient is not performing exercises until swelling and pain have completely subsided. Once the splint is discontinued, patients should be advised to avoid heavy gripping or grasping until grip strength has returned to normal. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Persistent symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the indications mentioned above, surgery may be needed in patients who do not respond to conservative therapy. Reattachment of the torn distal ligament, tendon graft repair, or arthrodesis (fusion) can be performed with a high success rate [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32068/abstract/18\">",
"     18",
"    </a>",
"    ]. Inadequately treated injuries or late presenting injuries may lead to chronic instability of the MCP joint, which can result in persistent pain, decreased pinch strength, or degenerative joint changes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strapless poles do not prevent ulnar collateral ligament injury in skiers because falls even when the hands are not in a strap can force radial deviation of the thumb [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32068/abstract/15\">",
"     15",
"    </a>",
"    ]. The risk of injury may be reduced by advising skiers to drop their poles during a fall.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14431451\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ulnar collateral ligament (UCL) injury is caused by forced abduction and hyperextension of the metacarpophalangeal (MP) joint, as might occur when a downhill skier falls and their thumb is thrust against a planted ski pole. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Mechanism of injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients complain of pain and swelling along the ulnar aspect of the MP joint initially. Weakness and instability may be the primary complaints of patients who present several weeks or months following the injury.",
"     </li>",
"     <li>",
"      Clinical findings include tenderness and swelling along the ulnar aspect of the metacarpophalangeal (MP) joint, weakness with pinch, and increased joint motion with valgus stress testing compared to the contralateral MP joint. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Standard posteroanterior, lateral, and oblique x-rays of the thumb are indicated in patients with suspected UCL injury. Stress radiographs may be needed to reveal increased joint laxity. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnostic imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Referral to a hand surgeon is prudent in most cases of suspected UCL injury. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Indications for surgical referral'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32068/abstract/1\">",
"      Richard JR. Gamekeeper's thumb: ulnar collateral ligament injury. Am Fam Physician 1996; 53:1775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32068/abstract/2\">",
"      Anderson D. Skier's thumb. Aust Fam Physician 2010; 39:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32068/abstract/3\">",
"      Engkvist O, Balkfors B, Lindsj&ouml; U. Thumb injuries in downhill skiing. Int J Sports Med 1982; 3:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32068/abstract/4\">",
"      Heyman P. Injuries to the Ulnar Collateral Ligament of the Thumb Metacarpophalangeal Joint. J Am Acad Orthop Surg 1997; 5:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32068/abstract/5\">",
"      Ritting AW, Baldwin PC, Rodner CM. Ulnar collateral ligament injury of the thumb metacarpophalangeal joint. Clin J Sport Med 2010; 20:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32068/abstract/6\">",
"      Rhee PC, Jones DB, Kakar S. Management of thumb metacarpophalangeal ulnar collateral ligament injuries. J Bone Joint Surg Am 2012; 94:2005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32068/abstract/7\">",
"      Heyman P, Gelberman RH, Duncan K, Hipp JA. Injuries of the ulnar collateral ligament of the thumb metacarpophalangeal joint. Biomechanical and prospective clinical studies on the usefulness of valgus stress testing. Clin Orthop Relat Res 1993; :165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32068/abstract/8\">",
"      Malik AK, Morris T, Chou D, et al. Clinical testing of ulnar collateral ligament injuries of the thumb. J Hand Surg Eur Vol 2009; 34:363.",
"     </a>",
"    </li>",
"    <li>",
"     Merrell, Greg and, Slade, Joseph, F.. Dislocations and Ligament Injuries in the Digits. In: Green's Operative Hand Surgery, Volume I, 6th ed, Wolfe, SW, Hotchkiss, RN, Pederson, WC, Kozin, SH (Eds), Elsevier, Philadelphia 2011. p.291.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32068/abstract/10\">",
"      Harley BJ, Werner FW, Green JK. A biomechanical modeling of injury, repair, and rehabilitation of ulnar collateral ligament injuries of the thumb. J Hand Surg Am 2004; 29:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32068/abstract/11\">",
"      Cooper JG, Johnstone AJ, Hider P, Ardagh MW. Local anaesthetic infiltration increases the accuracy of assessment of ulnar collateral ligament injuries. Emerg Med Australas 2005; 17:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32068/abstract/12\">",
"      Murphey SL, Hashimoto BE, Buckmiller J, et al. Ultrasonographic stress testing of ulnar collateral ligament injuries of the thumb. J Ultrasound Med 1997; 16:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32068/abstract/13\">",
"      Jones MH, England SJ, Muwanga CL, Hildreth T. The use of ultrasound in the diagnosis of injuries of the ulnar collateral ligament of the thumb. J Hand Surg Br 2000; 25:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32068/abstract/14\">",
"      Plancher KD, Ho CP, Cofield SS, et al. Role of MR imaging in the management of \"skier's thumb\" injuries. Magn Reson Imaging Clin N Am 1999; 7:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32068/abstract/15\">",
"      Fricker R, Hintermann B. Skier's thumb. Treatment, prevention and recommendations. Sports Med 1995; 19:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32068/abstract/16\">",
"      Landsman JC, Seitz WH Jr, Froimson AI, et al. Splint immobilization of gamekeeper's thumb. Orthopedics 1995; 18:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32068/abstract/17\">",
"      Arranz L&oacute;pez J, Alzaga F, Molina J. Acute ulnar collateral ligament injuries of the thumb metacarpophalangeal joint: an anatomical and clinical study. Acta Orthop Belg 1998; 64:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32068/abstract/18\">",
"      Sourmelis SV. Repair of the ulnar collateral ligament of the thumb. Technique and outcome in 21 patients followed for minimum 1.5 years. Acta Orthop Scand Suppl 1997; 275:52.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 250 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-61.234.146.186-EF0408A01F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_20_32068=[""].join("\n");
var outline_f31_20_32068=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14431451\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISM OF INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7703901\">",
"      Patient presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSTIC IMAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7703845\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      INDICATIONS FOR SURGICAL REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      NONSURGICAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Acute therapy, splinting, and rehabilitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Persistent symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14431451\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/250\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/250|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?36/31/37361\" title=\"diagnostic image 1\">",
"      Avulsion fracture of thumb proximal phalanx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?35/9/35984\" title=\"diagnostic image 2\">",
"      Avulsion fracture with ulnar collateral ligament injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/250|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/14/36064\" title=\"picture 1\">",
"      Valgus stress testing thumb",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/51/30527\" title=\"picture 2\">",
"      Anesthetic block trigger thumb",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/55/31615\" title=\"picture 3\">",
"      Thumb spica splint",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/9/23703?source=related_link\">",
"      Digital nerve block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9928?source=related_link\">",
"      Evaluation of the patient with thumb pain",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_20_32069="Caffeine: Pediatric drug information";
var content_f31_20_32069=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Caffeine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?24/34/25126?source=see_link\">",
"    see \"Caffeine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?41/51/42803?source=see_link\">",
"    see \"Caffeine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F144010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cafcit&reg;;",
"     </li>",
"     <li>",
"      Enerjets [OTC];",
"     </li>",
"     <li>",
"      No Doz&reg; Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Vivarin&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1057049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Central Nervous System Stimulant",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Diuretic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Respiratory Stimulant",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Oral, I.V.:  Apnea of prematurity:",
"     <b>",
"      Caffeine citrate:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Dose expressed as caffeine citrate; caffeine base is",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     the dose of the caffeine citrate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Loading dose: Minimum dose: 20 mg/kg caffeine citrate; loading doses as high as 80 mg/kg of caffeine citrate have been reported (Steer, 2004); some centers repeat a load of 20 mg/kg as caffeine citrate to a maximum cumulative dose load of 80 mg/kg as caffeine citrate in refractory patients (Schmidt, 2006; Schmidt, 2007; Steer, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maintenance dose: 5-10 mg/kg/day caffeine citrate once daily starting 24 hours after the loading dose; some centers increase maintenance dose in 5 mg/kg/day increments of caffeine citrate to a maximum of 20 mg/kg/day in refractory patients based on clinical response &plusmn; serum caffeine concentrations (Schmidt, 2006; Schmidt, 2007; Steer, 2004)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1057043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/34/25126?source=see_link\">",
"      see \"Caffeine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Stimulant/diuretic:",
"     <b>",
"      Caffeine sodium benzoate:",
"     </b>",
"     Adults: I.M., I.V.: 500 mg as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Treatment of spinal puncture headache:",
"     <b>",
"      Caffeine sodium benzoate:",
"     </b>",
"     Adults: I.V.: 500 mg as a single dose; may repeat in 4 hours if headache unrelieved",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F143990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caplet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NoDoz&reg; Maximum Strength, Vivarin&reg;: 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as citrate [preservative free]: 20 mg/mL (3 mL) [equivalent to 10 mg/mL caffeine base]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cafcit&reg;: 20 mg/mL (3 mL) [equivalent to 10 mg/mL caffeine base]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [with sodium benzoate]: Caffeine 125 mg/mL and sodium benzoate 125 mg/mL (2 mL); caffeine 121 mg/mL and sodium benzoate 129 mg/mL (2 mL) [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lozenge:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Enerjets&reg;: 75 mg (12s) [classic coffee, hazelnut cream, or mochamint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as citrate [preservative free]: 20 mg/mL (3 mL) [equivalent to 10 mg/mL caffeine base]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cafcit&reg;: 20 mg/mL (3 mL) [equivalent to 10 mg/mL caffeine base]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet: 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vivarin&reg;: 200 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F143978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Tablet, caffeine and sodium benzoate injection, injection, oral solution",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1057054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: May be administered without regard to feedings or meals; may administer injectable formulation (caffeine citrate) orally",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Caffeine citrate:",
"     </b>",
"     Infuse loading dose over at least 30 minutes; maintenance dose may be infused over at least 10 minutes; may administer without dilution or diluted with D",
"     <sub>",
"      5",
"     </sub>",
"     W to 10 mg caffeine citrate/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Caffeine sodium benzoate:",
"     </b>",
"     I.V. as slow direct injection; for spinal headaches, dilute in 1000 mL NS and infuse over 1 hour; follow with 1000 mL NS, infuse over 1 hour; administer I.M. undiluted",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F144036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Caffeine citrate: Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      50",
"     </sub>",
"     W, Intralipid&reg; 20%, Aminosyn&reg; 8.5%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Alprostadil, amikacin, aminophylline, calcium gluconate, cefotaxime, cimetidine, clindamycin, dexamethasone, dobutamine, dopamine, doxapram, epinephrine, fentanyl, gentamicin, heparin, isoproterenol, levofloxacin, lidoacine, metoclopramide, morphine, nitroprusside, pancuronium, penicillin G potassium, phenobarbital, phenylephrine, sodium bicarbonate, vancomycin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Acyclovir, furosemide, lorazepam, nitroglycerin, oxacillin, pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1057046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Caffeine citrate:",
"     </b>",
"     Injection and oral solution contain no preservatives; injection is chemically stable for at least 24 hours at room temperature when diluted to 10 mg/mL (as caffeine citrate) with D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      50",
"     </sub>",
"     W, Intralipid&reg; 20%, and Aminosyn&reg; 8.5%; also compatible with dopamine (600 mcg/mL), calcium gluconate 10%, heparin (1 unit/mL), and fentanyl (10 mcg/mL) at room temperature for 24 hours",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1057053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Treatment of idiopathic apnea of prematurity",
"     <b>",
"      (caffeine citrate)",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Emergency stimulant in acute circulatory failure; diuretic; treatment of spinal puncture headaches",
"     <b>",
"      (caffeine sodium benzoate)",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F144035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Primarily serum-concentration related.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Angina, arrhythmia (ventricular), chest pain, flushing, palpitation, sinus tachycardia, tachycardia (supraventricular), vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, delirium, dizziness, hallucinations, headache, insomnia, irritability, psychosis, restlessness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Esophageal sphincter tone decreased, gastritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Fasciculations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Intraocular pressure increased (&gt;180 mg caffeine), miosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Diuresis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1057058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to caffeine or any component; sodium benzoate salt form in neonates",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1057042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with a history of peptic ulcer, impaired renal or hepatic function, seizure disorders, or cardiovascular disease; avoid in patients with symptomatic cardiac arrhythmias",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1057041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Do not interchange the caffeine citrate salt formulation with the caffeine sodium benzoate formulation;",
"     </b>",
"     sodium benzoate has been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate also displaces bilirubin from protein-binding sites; avoid use of products containing sodium benzoate in neonates. During a Cafcit&reg; double-blind, placebo-controlled study, 6 of 85 patients developed necrotizing enterocolitis (NEC); 5 of these 6 patients had received caffeine citrate; although no causal relationship has been established, neonates who receive caffeine citrate should be closely monitored for the development of NEC. Caffeine serum levels should be closely monitored to optimize therapy and prevent serious toxicity.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F144025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (major), CYP2C9 (minor), CYP2D6 (minor), CYP2E1 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F143985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adenosine: Caffeine may diminish the therapeutic effect of Adenosine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Formoterol: Caffeine may enhance the adverse/toxic effect of Formoterol. Caffeine may enhance the hypokalemic effect of Formoterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indacaterol: Caffeine may enhance the adverse/toxic effect of Indacaterol. Caffeine may enhance the hypokalemic effect of Indacaterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid.  Specific dose adjustment recommendations are not presently available.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: May decrease the metabolism of Caffeine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Gemifloxacin; Levofloxacin (Systemic); Lomefloxacin; Moxifloxacin (Systemic); Nalidixic Acid; Ofloxacin (Systemic); Sparfloxacin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regadenoson: Caffeine may diminish the vasodilatory effect of Regadenoson.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Teriflunomide: May decrease the serum concentration of Caffeine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F143987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F143998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Caffeine crosses the placenta; serum levels in the fetus are similar to those in the mother. When large bolus doses are administered to animals, teratogenic effects have been reported. Similar doses are not probable following normal caffeine consumption and moderate consumption is not associated with congenital malformations, spontaneous abortions, preterm birth or low birth weight. According to one source, pregnant women who do not smoke or drink alcohol could consume &le;5 mg/kg of caffeine over the course of a day without reproductive risk. Other sources recommend limiting caffeine intake to &lt;150-200 mg/day. The half-life of caffeine is prolonged during the second and third trimesters of pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1057048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Heart rate, number and severity of apnea spells, serum caffeine levels",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1057052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Therapeutic: Apnea of prematurity: 8-20 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Potentially toxic: &gt;20 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Toxic: &gt;50 mcg/mL",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1057040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Increases levels of 3'5' cyclic AMP by inhibiting phosphodiesterase; CNS stimulant which increases medullary respiratory center sensitivity to carbon dioxide, stimulates central inspiratory drive, and improves skeletal muscle contraction (diaphragmatic contractility); prevention of apnea may occur by competitive inhibition of adenosine",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1057057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates: 0.8-0.9 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;9 months to Adults: 0.6 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 17%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Interconversion between caffeine and theophylline has been reported in preterm neonates (caffeine levels are &sim;25% of measured theophylline after theophylline administration and &sim;3% to 8% of caffeine would be expected to be converted to theophylline)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates: 72-96 hours (range: 40-230 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants &gt;9 months, Children, and Adults: 5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral: Within 30 minutes to 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates &le;1 month: 86% excreted unchanged in urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants &gt;1 month and Adults: Extensively liver metabolized to a series of partially demethylated xanthines and methyluric acids",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Neonates: 8.9 mL/hour/kg (range: 2.5-17)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 94 mL/hour/kg",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F11331429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 10 mg/mL oral solution of caffeine (as citrate) may be prepared from 10 g caffeine (anhydrous) combined with 10 g citric acid USP and dissolved in 1000 mL sterile water. Label &ldquo;shake well&rdquo; and &ldquo;refrigerate&rdquo;. Stable for 3 months (Nahata, 2004).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A 20 mg/mL oral solution of caffeine (as citrate) may be made from 5 g caffeine (anhydrous) combined with 5 g citric acid USP and dissolved in 250 mL sterile water. Stir solution until completely clear, then add a 2:1 mixture of simple syrup and cherry syrup in sufficient quantity to make 500 mL. Label &ldquo;shake well&rdquo; and &ldquo;refrigerate&rdquo;. Stable for 90 days (Eisenberg, 1984).",
"    </p>",
"    <div class=\"reference\">",
"     Eisenberg MG and Kang N, \"Stability of Citrated Caffeine Solutions for Injectable and Enteral Use,\"",
"     <i>",
"      Am J Hosp Pharm",
"     </i>",
"     , 1984, 41(11):2405-6.",
"     <span class=\"pubmed-id\">",
"      6507449",
"     </span>",
"    </div>",
"    <div class=\"reference\">",
"     Nahata MC, Pai VB, and Hipple TF,",
"     <i>",
"      Pediatric Drug Formulations",
"     </i>",
"     , 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bhatt-Mehta V and Schumacher RE, &ldquo;Treatment of Apnea of Prematurity,&rdquo;",
"      <i>",
"       Paediatr Drugs",
"      </i>",
"      , 2003, 5(3):195-210.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/20/32069/abstract-text/12608884 /pubmed\" id=\"12608884 \" target=\"_blank\">",
"        12608884",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Erenberg A, Leff RD, Haack DG, et al, &ldquo;Caffeine Citrate for the Treatment of Apnea of Prematurity: A Double-Blind, Placebo-Controlled Study,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2000, 20(6):644-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/20/32069/abstract-text/10853619/pubmed\" id=\"10853619\" target=\"_blank\">",
"        10853619",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kriter KE and Blanchard J, &ldquo;Management of Apnea in Infants,&rdquo;",
"      <i>",
"       Clin Pharm",
"      </i>",
"      , 1989, 8(8):577-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/20/32069/abstract-text/2670399/pubmed\" id=\"2670399\" target=\"_blank\">",
"        2670399",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schmidt B, Roberts RS, Davis P, et al, \"Caffeine Therapy for Apnea of Prematurity,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(20):2112-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/20/32069/abstract-text/16707748/pubmed\" id=\"16707748\" target=\"_blank\">",
"        16707748",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schmidt B, Roberts RS, Davis P, et al, \"Long-Term Effects of Caffeine Therapy for Apnea of Prematurity,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, 357(19):1893-902.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/20/32069/abstract-text/17989382/pubmed\" id=\"17989382\" target=\"_blank\">",
"        17989382",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Steer P, Flenady V, Shearman A, et al, \"High Dose Caffeine Citrate for Extubation of Preterm Infants: A Randomised Controlled Trial,\"",
"      <i>",
"       Arch Dis Child Fetal Neonatal Ed",
"      </i>",
"      , 2004, 89(6):F499-503.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/20/32069/abstract-text/15499141/pubmed\" id=\"15499141\" target=\"_blank\">",
"        15499141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13360 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-9070587B58-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_20_32069=[""].join("\n");
var outline_f31_20_32069=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144010\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057049\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442160\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057043\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143990\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143978\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057054\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144036\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057046\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057053\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144035\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057058\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057042\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057041\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144025\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143985\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143987\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143998\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057048\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057052\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057040\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057057\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11331429\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13360\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13360|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/34/25126?source=related_link\">",
"      Caffeine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?41/51/42803?source=related_link\">",
"      Caffeine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_20_32070="Overview and management strategies for the combined burn trauma patient";
var content_f31_20_32070=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview and management strategies for the combined burn trauma patient",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/20/32070/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/20/32070/contributors\">",
"     Steven E Wolf, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/20/32070/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/20/32070/contributors\">",
"     Marc G Jeschke, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/20/32070/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/20/32070/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?31/20/32070/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H2439903\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Burns complicate the management and outcomes of trauma patients [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32070/abstract/1\">",
"     1",
"    </a>",
"    ]. The initial management of a combined burn trauma (CBT) patient is stabilization and resuscitation of the patient, the same as for traumas without burn injuries. Management of the burn wounds is a secondary priority.",
"   </p>",
"   <p>",
"    The prevalence, management strategies, and outcomes for the CBT patient will be discussed here. The resuscitation and stabilization of multitrauma patients and the emergency management of burn patients are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=see_link\">",
"     \"Initial management of trauma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link\">",
"     \"Trauma management: Approach to the unstable child\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17242?source=see_link\">",
"     \"Emergency care of moderate and severe thermal burns in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44201?source=see_link\">",
"     \"Emergency care of moderate and severe thermal burns in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172491567\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of combined burn trauma (CBT) ranges from 0.4 to 5.8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32070/abstract/2\">",
"     2",
"    </a>",
"    ]. Approximately 1 to 5 percent of patients who sustain burn injuries incur penetrating",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    blunt trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32070/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Approximately 25 to 30 percent of those injured in a mass disaster or terrorist attack will sustain a moderate to severe burn injury [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32070/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2440770\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND TYPES OF INJURIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;CBT results from motor vehicle accidents with explosions, fires with structural collapse, falls while escaping a fire, electrical injuries and falls, scald burns during assaults, plane crashes, and explosions with airborne fragments and flames in civilian and combat settings [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32070/abstract/2-4,6,7\">",
"     2-4,6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common injuries associated with burns and the frequency in which they occur include [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32070/abstract/1,3,4\">",
"     1,3,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fractures: 45 to 64 percent",
"     </li>",
"     <li>",
"      Complex soft tissue injuries: 36 to 52 percent",
"     </li>",
"     <li>",
"      Traumatic brain injury: 17 to 26 percent",
"     </li>",
"     <li>",
"      Thoracic and abdominal injuries: 4 to 24 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2441258\">",
"    <span class=\"h1\">",
"     STABILIZATION AND EARLY MANAGEMENT STRATEGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;An understanding of the independent temporal changes of each injury (eg, penetrating, blunt, burn) and how they interact with each other allows the surgeon to devise the optimal management strategy (",
"    <a class=\"graphic graphic_figure graphicRef75896 \" href=\"UTD.htm?21/42/22190\">",
"     figure 1",
"    </a>",
"    ). The highest priority (after airway, breathing, and intravenous access) in the setting of CBT is the assessment and treatment of penetrating injuries, followed by blunt injuries, then the management of the burn. The approach to resuscitating and stabilizing a CBT patient parallels the procedures for the emergent management of a burn patient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=see_link&amp;anchor=H1929690#H1929690\">",
"     \"Initial management of trauma in adults\", section on 'Primary evaluation and management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link&amp;anchor=H9#H9\">",
"     \"Trauma management: Approach to the unstable child\", section on 'Primary survey'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17242?source=see_link\">",
"     \"Emergency care of moderate and severe thermal burns in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44201?source=see_link\">",
"     \"Emergency care of moderate and severe thermal burns in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The key to the initial management of a CBT patient is that the burn wounds do not interfere with the basic resuscitation and stabilization of the multitrauma patient. As an example, the presence of burned skin should not preclude attempts at intravenous access, control of hemorrhaging sites, coverage of open fractures and wounds, and fixation of closed fractures.",
"   </p>",
"   <p>",
"    The approaches to the assessment and management of specific injuries are discussed individually in separate topics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H92076309\">",
"    <span class=\"h1\">",
"     IMMEDIATE BURN WOUND MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;After performing the primary and secondary surveys recommended by the American College of Surgeons Advanced Trauma Life Support (ATLS) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32070/abstract/8\">",
"     8",
"    </a>",
"    ] and while other injuries are being addressed, the burn wounds should be simply covered with sterile dry dressings.",
"   </p>",
"   <p>",
"    CBT patients are treated for pain while in the emergency department. The approaches to pain control and local treatment of burns are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/50/38695?source=see_link\">",
"     \"Paradigm-based treatment approaches for burn pain control\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34169?source=see_link\">",
"     \"Burn pain: Principles of pharmacologic and nonpharmacologic management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29225?source=see_link\">",
"     \"Local treatment of burns: Topical antimicrobial agents and dressings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H92085305\">",
"    <span class=\"h2\">",
"     Eschar management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The secondary survey of hands, extremities, and chest includes an evaluation for increased edema formation and increased tissue pressures under a relatively non-yielding eschar. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17242?source=see_link&amp;anchor=H25#H25\">",
"     \"Emergency care of moderate and severe thermal burns in adults\", section on 'Escharotomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If respiratory compromise occurs secondary to a chest wall eschar, longitudinal incisions are made in the mid-axillary line and extended for the length of the eschar. If vascular compromise is identified in an extremity or hand, an escharotomy is performed using longitudinal incisions on the medial and lateral aspects of the extremity and digits.",
"   </p>",
"   <p>",
"    The escharotomy incisions on the extremities should be sited such that they do not interfere with potential incisions for orthopaedic repairs of fractures. A description of the escharotomy of the hand is discussed elsewhere and can be used as the model for performing this procedure along the chest wall and extremities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/62/18409?source=see_link&amp;anchor=H15#H15\">",
"     \"Primary operative management of hand burns\", section on 'Escharotomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, we perform an escharotomy within six hours for extremities with full-thickness burns as these eschars will be excised in the coming days, thus cosmetic considerations are not at issue. For other settings, we perform an escharotomy upon recognition of a potential for respiratory or vascular compromise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2441359\">",
"    <span class=\"h2\">",
"     Transfer guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transfer to a burn center for specialized burn management should proceed within 24 hours after the resuscitation and stabilization for CBT patients with greater than 10 percent total body surface area (TBSA) burns, per the triage guidelines for mass casualties with burns developed by the American Burn Association [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32070/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2441128\">",
"    <span class=\"h1\">",
"     MANAGEMENT STRATEGIES FOR COMPLICATED SETTINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Post-stabilization management strategies for combined burn trauma (CBT) patients are based upon the severity and the type of associated injuries. Adjustment to standard burn management is dictated by severe injuries, including closed head injury and open fractures, which impact upon the timing of overall management. Burn patients with spinal cord injuries are managed with stabilization and reduction of the spinal fracture and routine burn wound management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26810?source=see_link&amp;anchor=H19#H19\">",
"     \"Acute traumatic spinal cord injury\", section on 'Management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29225?source=see_link\">",
"     \"Local treatment of burns: Topical antimicrobial agents and dressings\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Options to standard venous thromboembolism prophylaxis must be considered, and the high metabolic demands of a CBT patient must be addressed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2439939\">",
"    <span class=\"h2\">",
"     Closed head injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Burns associated with a head injury present a particular challenge, as the optimal treatment for the intracranial injury is fluid restriction while the optimal treatment for the burn injury is fluid resuscitation. A balance must be achieved to avoid excessive hypervolemia.",
"   </p>",
"   <p>",
"    A patient with a closed head injury and a burn is best managed by administering isotonic fluid and maintaining urine output at 0.5 to 1.0",
"    <span class=\"nowrap\">",
"     cc/kg/hour.",
"    </span>",
"    Management of the head injury takes priority over burn injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/2/35882?source=see_link&amp;anchor=H15#H15\">",
"     \"Management of acute severe traumatic brain injury\", section on 'Intracranial pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10068673\">",
"    <span class=\"h2\">",
"     Open and closed fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Open reduction and internal fixation, if required for fracture reduction and immobilization, should be performed within the first 24 hours after injury. This approach should be followed for fractures in burned and unburned areas. This approach allows for local physiologic stabilization before bacteremia develops and reduces the risk of osteomyelitis [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32070/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If internal fixation is not possible, fracture stabilization with external fixation may be the optimal approach to allow for bone healing as well as access to the skin for burn wound management [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32070/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10068606\">",
"    <span class=\"h2\">",
"     Venous thromboembolism prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Venous thromboembolism prophylaxis (VTE) can complicate burn wound excision, which is associated with hemorrhage, fluid shifts, coagulopathies, and blood transfusions. A vena cava filter is an alternative to medical anticoagulation. The author prefers a vena cava filter for patients with brain hemorrhage, otherwise medical anticoagulation is administered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/28/16840?source=see_link\">",
"     \"Placement of inferior vena cava filters and their complications\"",
"    </a>",
"    .) In anticoagulated patients, burn wound management can be adapted to smaller but more frequent excisions and skin grafting to minimize blood loss and physiological derangements [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32070/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2439960\">",
"    <span class=\"h2\">",
"     Hypermetabolism and nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with moderate to severe burns and associated traumatic injuries are at risk for the development of the hypermetabolic response [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32070/abstract/13-18\">",
"     13-18",
"    </a>",
"    ]. In general, metabolic derangements that occur to some extent in all injuries will be dominated by the burn component, and CBT patients should be treated in accordance with practices common to those with moderate to severe burns.",
"   </p>",
"   <p>",
"    The modulation of the hypermetabolic response in CBT patients includes burn excision and grafting and aggressive enteral feedings or parenteral nutritional support when the gastrointestinal tract cannot be utilized (25",
"    <span class=\"nowrap\">",
"     kcal/kg",
"    </span>",
"    body weight per day plus 40 kcal per percent TBSA burn per day) within three days of injury [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32070/abstract/18\">",
"     18",
"    </a>",
"    ]. Environmental thermoregulation (eg, room temperature set at",
"    <span class=\"nowrap\">",
"     90&deg;F/32&deg;C)",
"    </span>",
"    to minimize the profound water and heat loss associated with burns is instituted upon the patient&rsquo;s admission to the emergency department and continued throughout the intensive care admission.",
"   </p>",
"   <p>",
"    A review on the hypermetabolic response to the burn injury and the nutritional requirements and nutritional support are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22330?source=see_link\">",
"     \"Hypermetabolic response to severe burn injury: Recognition and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4215?source=see_link\">",
"     \"Overview of nutritional support for moderate to severe burn patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/8/11401?source=see_link\">",
"     \"Nutritional demands and enteral formulas for moderate to severe burn patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13831?source=see_link\">",
"     \"Nutrition support in critically ill patients: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6664?source=see_link\">",
"     \"Perioperative nutritional support\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H92085241\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injury severity scores have been devised to quantitate injury and predict outcome for multitrauma patients, however, each scoring system has limitations [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32070/abstract/19-23\">",
"     19-23",
"    </a>",
"    ]. Trauma scores have not been typically used to quantitate burn injuries as burns are assessed as total body surface area burned.",
"   </p>",
"   <p>",
"    Examples of scoring systems include the anatomical scoring system Injury Severity Score (ISS), the physiologic scoring system Revised Trauma Score (RTS), TRISS (age plus ISS and RTS), and A Severity Characterization of Trauma (ASCOT) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32070/abstract/19-25\">",
"     19-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    TRISS (",
"    <a class=\"external\" href=\"file://www.trauma.org/archive/scores/triss.html\">",
"     www.trauma.org/archive/scores/triss.html",
"    </a>",
"    ) can accurately predict the probability of survival in blunt trauma patients and provides a reasonable assessment of survival in patients with penetrating injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32070/abstract/19,26\">",
"     19,26",
"    </a>",
"    ]. Burns are a component of ISS, but the contribution of the burn injury to TRISS is often inaccurate and cannot be used for prognostication.",
"   </p>",
"   <p>",
"    All components of injury will contribute to the mortality rate, however, patients with combined burn trauma (CBT) have a higher mortality rate compared with burn only and trauma only patients [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32070/abstract/2,6\">",
"     2,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective review of 5462 CBT patients, 7324 burn only patients, and 411,173 trauma only patients from the National Trauma Data Bank (NTDB) found a higher mortality rate for CBT patients compared with burn only and trauma only patients (11 versus 3 and 5 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?31/20/32070/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective review of 751 military and civilian patients, for those with moderate to severe burns (total body surface area &gt;20 percent), the consequences of the burn dominated all injuries after initial stabilization [",
"      <a class=\"abstract\" href=\"UTD.htm?31/20/32070/abstract/20\">",
"       20",
"      </a>",
"      ]. Injury Severity Score (ISS) and non-burn Acute Injury Score (AIS) were not associated with an increase in mortality in the multivariate analysis. The total body surface area burn (TBSA) for survivors was significantly lower compared with those who died (11 versus 52 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An acute abdominal catastrophe, such as intra-abdominal hypertension or an abdominal compartment syndrome, can occur in CBT patients even in the absence of intra-abdominal trauma. An abdominal catastrophe can occur when the intra-abdominal pressure is &gt;30 mmHg. A retrospective review of 1825 burn patients admitted to the US Army Institute of Surgical Research Burn Center found that acute abdominal catastrophe without intra-abdominal trauma occurred in 2.8 percent (51 patients), and the mortality rate was 78 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32070/abstract/27\">",
"     27",
"    </a>",
"    ]. Another 69 patients (3.8 percent) developed intra-abdominal complications without an acute abdominal catastrophe, with an associated mortality rate of 20 percent. The risk of an abdominal catastrophe increases with increasing burn size and can be avoided by judicious use of resuscitation fluid. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20761?source=see_link\">",
"     \"Abdominal compartment syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2439967\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of burned skin should not preclude attempts at intravenous access, control of hemorrhaging sites, coverage of open fractures and wounds, and fixation of closed fractures. (See",
"      <a class=\"local\" href=\"#H2441258\">",
"       'Stabilization and early management strategies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who sustain burn injuries with other injuries, the burn wounds are covered with a sterile dry dressing until the patient has been resuscitated and stabilized. (See",
"      <a class=\"local\" href=\"#H92076309\">",
"       'Immediate burn wound management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Penetrating injuries, blunt trauma, head injuries, and open fractures take precedent over the management of burns. (See",
"      <a class=\"local\" href=\"#H2441128\">",
"       'Management strategies for complicated settings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypermetabolic response in the combined burn trauma patient can be mitigated by excision of the burn and skin grafting and initiation of enteral or parental nutritional support within three days of the injury. Environmental thermoregulation (eg, room temperature set at",
"      <span class=\"nowrap\">",
"       90&deg;F/32&deg;C)",
"      </span>",
"      is instituted immediately upon arrival at the emergency department and continued throughout the intensive care admission to minimize heat and water loss. (See",
"      <a class=\"local\" href=\"#H2439960\">",
"       'Hypermetabolism and nutrition'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32070/abstract/1\">",
"      Purdue GF, Hunt JL. Multiple trauma and the burn patient. Am J Surg 1989; 158:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32070/abstract/2\">",
"      Santaniello JM, Luchette FA, Esposito TJ, et al. Ten year experience of burn, trauma, and combined burn/trauma injuries comparing outcomes. J Trauma 2004; 57:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32070/abstract/3\">",
"      Brandt CP, Yowler CJ, Fratianne RB. Burns with multiple trauma. Am Surg 2002; 68:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32070/abstract/4\">",
"      Rosenkranz KM, Sheridan R. Management of the burned trauma patient: balancing conflicting priorities. Burns 2002; 28:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32070/abstract/5\">",
"      ABA Board of Trustees, Committee on Organization and Delivery of Burn Care. Disaster management and the ABA Plan. J Burn Care Rehabil 2005; 26:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32070/abstract/6\">",
"      Hawkins A, Maclennan PA, McGwin G Jr, et al. The impact of combined trauma and burns on patient mortality. J Trauma 2005; 58:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32070/abstract/7\">",
"      Kauvar DS, Wolf SE, Wade CE, et al. Burns sustained in combat explosions in Operations Iraqi and Enduring Freedom (OIF/OEF explosion burns). Burns 2006; 32:853.",
"     </a>",
"    </li>",
"    <li>",
"     Amercian College of Surgeons, Advanced Trauma Life Support (ATLS), 8th edition. www.facs.org/trauma/atls/index.html (Accessed on August 24, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32070/abstract/9\">",
"      Pape HC. Early definitive femoral fracture fixation in polytrauma: Advantages vs systemic adverse effects. Current Orthopaedics 2001; 15:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32070/abstract/10\">",
"      Pape HC, Tornetta P 3rd, Tarkin I, et al. Timing of fracture fixation in multitrauma patients: the role of early total care and damage control surgery. J Am Acad Orthop Surg 2009; 17:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32070/abstract/11\">",
"      Scalea TM, Boswell SA, Scott JD, et al. External fixation as a bridge to intramedullary nailing for patients with multiple injuries and with femur fractures: damage control orthopedics. J Trauma 2000; 48:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32070/abstract/12\">",
"      Hart DW, Wolf SE, Beauford RB, et al. Determinants of blood loss during primary burn excision. Surgery 2001; 130:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32070/abstract/13\">",
"      Hart DW, Wolf SE, Mlcak R, et al. Persistence of muscle catabolism after severe burn. Surgery 2000; 128:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32070/abstract/14\">",
"      Murray CK, Hoffmaster RM, Schmit DR, et al. Evaluation of white blood cell count, neutrophil percentage, and elevated temperature as predictors of bloodstream infection in burn patients. Arch Surg 2007; 142:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32070/abstract/15\">",
"      Wolf SE, Jeschke MG, Rose JK, et al. Enteral feeding intolerance: an indicator of sepsis-associated mortality in burned children. Arch Surg 1997; 132:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32070/abstract/16\">",
"      Greenhalgh DG, Saffle JR, Holmes JH 4th, et al. American Burn Association consensus conference to define sepsis and infection in burns. J Burn Care Res 2007; 28:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32070/abstract/17\">",
"      Jeschke MG, Mlcak RP, Finnerty CC, et al. Burn size determines the inflammatory and hypermetabolic response. Crit Care 2007; 11:R90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32070/abstract/18\">",
"      Williams FN, Jeschke MG, Chinkes DL, et al. Modulation of the hypermetabolic response to trauma: temperature, nutrition, and drugs. J Am Coll Surg 2009; 208:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32070/abstract/19\">",
"      Millham FH, LaMorte WW. Factors associated with mortality in trauma: re-evaluation of the TRISS method using the National Trauma Data Bank. J Trauma 2004; 56:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32070/abstract/20\">",
"      Wolf SE, Kauvar DS, Wade CE, et al. Comparison between civilian burns and combat burns from Operation Iraqi Freedom and Operation Enduring Freedom. Ann Surg 2006; 243:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32070/abstract/21\">",
"      Moreau AR, Westfall PH, Cancio LC, Mason AD Jr. Development and validation of an age-risk score for mortality predication after thermal injury. J Trauma 2005; 58:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32070/abstract/22\">",
"      Chawda MN, Hildebrand F, Pape HC, Giannoudis PV. Predicting outcome after multiple trauma: which scoring system? Injury 2004; 35:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32070/abstract/23\">",
"      Rutledge R, Osler T, Emery S, Kromhout-Schiro S. The end of the Injury Severity Score (ISS) and the Trauma and Injury Severity Score (TRISS): ICISS, an International Classification of Diseases, ninth revision-based prediction tool, outperforms both ISS and TRISS as predictors of trauma patient survival, hospital charges, and hospital length of stay. J Trauma 1998; 44:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32070/abstract/24\">",
"      Champion HR, Copes WS, Sacco WJ, et al. Improved predictions from a severity characterization of trauma (ASCOT) over Trauma and Injury Severity Score (TRISS): results of an independent evaluation. J Trauma 1996; 40:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32070/abstract/25\">",
"      Champion HR, Sacco WJ, Copes WS, et al. A revision of the Trauma Score. J Trauma 1989; 29:623.",
"     </a>",
"    </li>",
"    <li>",
"     Trauma Score - Injury Severity Score: TRISS. www.trauma.org/archive/scores/triss.html (Accessed on August 29, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32070/abstract/27\">",
"      Markell KW, Renz EM, White CE, et al. Abdominal complications after severe burns. J Am Coll Surg 2009; 208:940.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14988 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-8189A37D88-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_20_32070=[""].join("\n");
var outline_f31_20_32070=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2439967\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2439903\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H172491567\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2440770\">",
"      ETIOLOGY AND TYPES OF INJURIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2441258\">",
"      STABILIZATION AND EARLY MANAGEMENT STRATEGIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H92076309\">",
"      IMMEDIATE BURN WOUND MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H92085305\">",
"      Eschar management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2441359\">",
"      Transfer guidelines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2441128\">",
"      MANAGEMENT STRATEGIES FOR COMPLICATED SETTINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2439939\">",
"      Closed head injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10068673\">",
"      Open and closed fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10068606\">",
"      Venous thromboembolism prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2439960\">",
"      Hypermetabolism and nutrition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H92085241\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2439967\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/14988\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/14988|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/42/22190\" title=\"figure 1\">",
"      Burns and multitrauma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20761?source=related_link\">",
"      Abdominal compartment syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26810?source=related_link\">",
"      Acute traumatic spinal cord injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34169?source=related_link\">",
"      Burn pain: Principles of pharmacologic and nonpharmacologic management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17242?source=related_link\">",
"      Emergency care of moderate and severe thermal burns in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44201?source=related_link\">",
"      Emergency care of moderate and severe thermal burns in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22330?source=related_link\">",
"      Hypermetabolic response to severe burn injury: Recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=related_link\">",
"      Initial management of trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29225?source=related_link\">",
"      Local treatment of burns: Topical antimicrobial agents and dressings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/2/35882?source=related_link\">",
"      Management of acute severe traumatic brain injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13831?source=related_link\">",
"      Nutrition support in critically ill patients: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/8/11401?source=related_link\">",
"      Nutritional demands and enteral formulas for moderate to severe burn patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4215?source=related_link\">",
"      Overview of nutritional support for moderate to severe burn patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/50/38695?source=related_link\">",
"      Paradigm-based treatment approaches for burn pain control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6664?source=related_link\">",
"      Perioperative nutritional support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/28/16840?source=related_link\">",
"      Placement of inferior vena cava filters and their complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/62/18409?source=related_link\">",
"      Primary operative management of hand burns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=related_link\">",
"      Trauma management: Approach to the unstable child",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_20_32071="Bendamustine: Drug information";
var content_f31_20_32071=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Bendamustine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?40/55/41844?source=see_link\">",
"    see \"Bendamustine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F5957167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Treanda&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F15065726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Treanda&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F5957171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent;",
"     </li>",
"     <li>",
"      Antineoplastic Agent, Alkylating Agent;",
"     </li>",
"     <li>",
"      Antineoplastic Agent, Alkylating Agent (Nitrogen Mustard)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F5958743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Chronic lymphocytic leukemia (CLL):",
"     </b>",
"     I.V.:100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 30 minutes on days 1 and 2 of a 28-day treatment cycle (as a single agent) for up to 6 cycles (Knauf, 2009; Knauf, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      CLL, relapsed/refractory (unlabeled dosing):",
"     </b>",
"     I.V.: 70 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on days 1 and 2 of a 28-day treatment cycle (in combination with rituximab) for up to 6 cycles (Fischer, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Non-Hodgkin lymphomas:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Lymphoma, indolent B-cell, refractory:",
"     </i>",
"     120 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 60 minutes on days 1 and 2 of a 21-day treatment cycle (as a single agent) for up to 8 cycles (Kahl, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Lymphoma, indolent B-cell, follicular, or mantle cell, first-line (unlabeled use):",
"     </i>",
"     90 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on days 1 and 2 of a 28-day treatment cycle (in combination with rituximab) for up to 6 cycles (Rummel, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Lymphoma, follicular, relapsed or refractory (unlabeled use):",
"     </i>",
"     90 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on days 1 and 2 of a 35-day treatment cycle (in combination with bortezomib and rituximab) for 5 cycles (Fowler, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Lymphoma, mantle cell, relapsed or refractory (unlabeled use):",
"     </i>",
"     90 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 30 minutes on days 2 and 3 of a 28-day treatment cycle (in combination with rituximab) for up to 4 cycles (Rummel, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hodgkin lymphoma, relapsed or refractory (unlabeled use):",
"     </b>",
"     I.V.: 120 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on days 1 and 2 of a 28-day treatment cycle for up to 6 cycles (Moskowitz, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Multiple myeloma, salvage therapy (unlabeled use):",
"     </b>",
"     I.V.: 90-100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on days 1 and 2 of a 28-day treatment cycle for at least 2 cycles (Knop, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Waldenstr&ouml;m&rsquo;s macroglobulinemia, refractory (unlabeled use):",
"     </b>",
"     I.V.: 90 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on days 1 and 2 of a 28-day treatment cycle (in combination with rituximab) for 6 cycles (Treon, 2011)",
"     <b>",
"      or",
"     </b>",
"     90 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 30 minutes on days 2 and 3 of a 28-day treatment cycle (in combination with rituximab) for 4 cycles (Rummel, 2005)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F5957380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F5957381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;40 mL/minute: Use is not recommended  in the U.S. and Canadian manufacturers' labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Study data suggest minor changes in systemic exposure may occur with mild-to-moderate renal impairment. Based on a pharmacokinetic study (patients receiving 120 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     for 2 days every 21 days), only slight differences in bendamustine AUC and C",
"     <sub>",
"      max",
"     </sub>",
"     were demonstrated in patients with mild (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 to &le;80 mL/minute) and moderate (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;30 to &le;50 mL/minute) renal dysfunction, compared to patients with normal renal function (Owen, 2010). A retrospective study of bendamustine in CLL and NHL patients with renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;40 mL/minute) compared to those without (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;60 mL/minute) found no significant difference in lab toxicities in CLL patients with renal impairment compared to those without renal impairment, although an increase in grades 3/4 thrombocytopenia was noted in NHL patients and grades 3/4 BUN increases were higher when combining data for CLL and NHL (Nordstrom, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Note:",
"     </b>",
"     UK manufacturer's labeling (Levact [prescribing information], October, 2010) recommends no dosage adjustment for patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;10 mL/minute.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F5957382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mild  impairment: Per U.S. and Canadian manufacturers' labeling, use with caution. However, a pharmacokinetic study showed only slight differences in bendamustine AUC and C",
"     <sub>",
"      max",
"     </sub>",
"     in  patients with mild hepatic impairment (defined in the study as total bilirubin 1-1.5 times ULN or AST greater than ULN), compared to patients with normal hepatic function (Owen, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate  impairment (AST or ALT 2.5-10 times ULN and total bilirubin 1.5-3 times ULN): Use is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe impairment (total bilirubin &gt;3 times ULN): Use is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F5957403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      Infusion reactions:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Grade 1 or 2: Consider premedication with antihistamines, antipyretics, and corticosteroids in subsequent cycles",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Grade 3 or 4: Consider discontinuing treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      Treatment delay:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Hematologic toxicity &ge;grade 4: Delay treatment until resolves (ANC &ge;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , platelets &ge;75,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Nonhematologic toxicity &ge;grade 2 (clinically significant): Delay treatment until resolves to &le;grade 1",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      Dose modification CLL:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Hematologic toxicity &ge;grade 3: Reduce dose to 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on days 1 and 2 of each treatment cycle. For recurrent hematologic toxicity (&ge;grade 3), further reduce dose to 25 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on days 1 and 2 of the treatment cycle. May cautiously re-escalate dose in subsequent cycles.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Nonhematologic toxicity &ge;grade 3 (clinically significant): Reduce dose to 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on days 1 and 2 of the treatment cycle with discretion. May cautiously re-escalate dose in subsequent cycles.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      Dose modification in NHL:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Hematologic toxicity grade 4: Reduce dose to 90 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on days 1 and 2 of each treatment cycle. For recurrent hematologic toxicity (grade 4), further reduce dose to 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on days 1 and 2 of each treatment cycle.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Nonhematologic toxicity &ge;grade 3: Reduce dose to 90 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on days 1 and 2 of the treatment cycle with discretion. For recurrent toxicity &ge;grade 3, further reduce dose to 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on days 1 and 2 of each treatment cycle.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F5957484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Treanda&reg;: 25 mg, 100 mg [contains mannitol]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F5957169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5957404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Infuse over 30 minutes for the treatment of CLL and over 60 minutes for NHL; administration times for unlabeled uses/doses vary by protocol. Consider premedication with antihistamines, antipyretics, and corticosteroids for patients with a previous grade 1 or 2 infusion reaction to bendamustine. Avoid extravasation; monitor I.V. site for redness, swelling, or pain.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F5957370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS, D",
"     <sub>",
"      2.5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F5957173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of chronic lymphocytic leukemia (CLL); treatment of progressed indolent B-cell non-Hodgkin&rsquo;s lymphoma (NHL)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F5957174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of relapsed or refractory Hodgkin lymphoma; treatment of mantle cell lymphoma; salvage therapy for relapsed multiple myeloma; first-line therapy for follicular lymphoma; treatment of Waldenstr&ouml;m&rsquo;s macroglobulinemia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5957165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Bendamustine may be confused with brentuximab, carmustine, lomustine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the  Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F5957206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Peripheral edema (&le;13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fatigue (9% to 57%), fever (24% to 34%), headache (&le;21%), chills (6% to 14%), dizziness (&le;14%), insomnia (&le;13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Rash (8% to 16%; grades 3/4: &le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Dehydration (&le;14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (20% to 75%), vomiting (16% to 40%), diarrhea (9% to 37%), constipation (&le;29%), anorexia (&le;23%), weight loss (7% to 18%), stomatitis (&le;15%), abdominal pain (5% to 13%), appetite loss (&le;13%), dyspepsia (&le;11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Myelosuppression (nadir: in week 3), lymphopenia (68% to 99%; grades 3/4: 47% to 94%), leukopenia (61% to 94%; grades 3/4: 28% to 56%), anemia (88% to 89%; grades 3/4: 11% to 13%), thrombocytopenia (77% to 86%; grades 3/4: 11% to 25%), neutropenia (75% to 86%; grades 3/4: 43% to 60%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: Bilirubin increased (&le;34%; grades 3/4: 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Back pain (&le;14%), weakness (8% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Cough (4% to 22%), dyspnea (&le;16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Tachycardia (&le;7%), hypotension (&le;6%), chest pain (&le;6%), hypertension aggravated (&le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Anxiety (&le;8%), depression (&le;6%), pain (&le;6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Pruritus (5% to 6%), dry skin (&le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hypokalemia (&le;9%), hyperuricemia (&le;7%; grades 3/4: 2%), hyperglycemia (grades 3/4: &le;3%), hypocalcemia (grades 3/4: &le;2%), hyponatremia (grades 3/4: &le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Gastroesophageal reflux disease (&le;10%), xerostomia (9%), taste alteration (&le;7%), oral candidiasis (&le;6%), abdominal distention (&le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Urinary tract infection (&le;10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Febrile neutropenia (3% to 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: ALT increased (grades 3/4: &le;3%), AST increased (grades 3/4: &le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Infusion site pain (&le;6%), catheter site pain (&le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (&le;6%), bone pain (&le;5%), limb pain (&le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Creatinine increased (grades 3/4: &le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Upper respiratory infection (10%), sinusitis (&le;9%), pharyngolaryngeal pain (&le;8%), pneumonia (&le;8%), nasopharyngitis (6% to 7%), wheezing (&le;5%), nasal congestion (&le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Herpes infection (3% to 10%), infection (&le;6%; grades 3/4: 2%), hypersensitivity (&le;5%; grades 3/4: 1%), diaphoresis (&le;5%), night sweats (&le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Acute myeloid leukemia, acute renal failure, alopecia, anaphylaxis, bronchial carcinoma, bullous exanthema, cardiac failure, dermatitis, erythema, hemolysis, hepatitis B virus reactivation, infusion reaction, injection/infusion site reaction (erythema, irritation, pain, phlebitis, pruritus, swelling), malaise, mucosal inflammation, myelodysplastic syndrome, myeloproliferative disorders, pulmonary fibrosis, sepsis, septic shock, skin necrosis, somnolence, Stevens-Johnson syndrome, toxic epidermal necrolysis, toxic skin reactions, tumor lysis syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F5957180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to bendamustine, mannitol, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F5957181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression: Myelosuppression (neutropenia, thrombocytopenia, and anemia) is a common toxicity; may require therapy delay and/or dose reduction; monitor blood counts. Complications due to febrile neutropenia and severe thrombocytopenia have been reported. ANC should recover to &ge;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     and platelets to &ge;75,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     prior to cycle initiation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dermatologic toxicity: Rash, toxic skin reactions and bullous exanthema have been reported with monotherapy and in combination with other antineoplastics; may be progressive or worsen with continued treatment; monitor closely. The risk for severe skin toxicity is increased with concurrent use of allopurinol and other medications known to cause skin toxicity; Stevens-Johnson syndrome and toxic epidermal necrolysis (TEN) have been reported. TEN has also been reported when used in combination with rituximab. Discontinue bendamustine treatment for severe or progressive skin reaction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extravasation: Erythema, marked swelling, and pain have been reported with extravasation; monitor infusion site; avoid extravasation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity/infusion reaction: Infusion reactions, which may include chills, fever, pruritus, and rash, are common. Rarely, anaphylactic and anaphylactoid reactions have occurred, particularly with the second or subsequent cycle(s). In general, patients who experienced grade 3 or higher allergic reactions were not rechallenged. Consider premedication with antihistamines, antipyretics and corticosteroids for patients with a history of grade 1 or 2 infusion reaction. Discontinue for severe allergic reaction; consider discontinuation with grade 3 or 4 infusion reaction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypokalemia: Has been reported with use; monitor potassium closely in patients with cardiac disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infection: Pneumonia and sepsis have been reported with use; may require hospitalization. Septic shock and fatalities due to infection have occurred. Patients with myelosuppression are more susceptible to infection; monitor closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Malignancy: Malignancies (including myelodysplastic syndrome, myeloproliferative disorders, acute myeloid leukemia and bronchial cancer) and premalignant diseases have been reported in patients who have received bendamustine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tumor lysis syndrome: Tumor lysis syndrome (usually occurring in the first treatment cycle) may occur as a consequence of antineoplastic treatment, including treatment with bendamustine. May lead to life-threatening acute renal failure; adequate hydration and prophylactic measures (eg, allopurinol) should be instituted prior to treatment in high-risk patients; monitor closely.",
"     <b>",
"      Note:",
"     </b>",
"     Allopurinol may increase the risk for bendamustine skin toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Per manufacturer&rsquo;s labeling, use with caution in patients with mild hepatic impairment. However, a pharmacokinetic study showed only slight differences in bendamustine AUC and C",
"     <sub>",
"      max",
"     </sub>",
"     in patients with mild hepatic impairment (defined in the study as total bilirubin 1-1.5 times ULN or AST greater than ULN), as compared to patients with normal hepatic function (Owen, 2010). Use is not recommended in patients with moderate (AST or ALT 2.5-10 times ULN and total bilirubin 1.5-3 times ULN) or severe (total bilirubin &gt;3 times ULN) hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with mild-to-moderate renal impairment. The U.S. and Canadian product labels do not recommend use in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;40 mL/minute. A pharmacokinetic study illustrated only slight differences in bendamustine AUC and C",
"     <sub>",
"      max",
"     </sub>",
"     in patients with mild (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 to &le;80 mL/minute) and moderate (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;30 to &le;50 mL/minute) renal dysfunction, compared to patients with normal renal function (Owen, 2010). A retrospective safety study found no significant difference in lab toxicities between CLL patients with renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;40 mL/minute) compared to those without renal impairment, although an increase in grades 3/4 thrombocytopenia and grades 3/4 BUN increases were detected in patients with renal impairment (Nordstrom, 2012); monitor blood counts and renal function.",
"     <b>",
"      Note:",
"     </b>",
"     UK labeling (Levact prescribing information, October, 2010) recommends no dosage adjustment for patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;10 mL/minute.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F5957266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of BCRP, CYP1A2 (minor), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F5957265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: May enhance the adverse/toxic effect of Bendamustine. Specifically, the risk of severe skin reactions may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inducers (Strong): May decrease the serum concentration of Bendamustine. Concentrations of active metabolites may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Strong): May increase the serum concentration of Bendamustine. Concentrations of the active metabolites of bendamustine may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F5957175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5957176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic and nonteratogenic events were observed in animal reproduction studies following intraperitoneal dosing. May cause fetal harm if administered during pregnancy. For women and men of reproductive potential, the U.S. labeling recommends effective contraception during and for 3 months after treatment. The Canadian labeling recommends effective contraception beginning 2 weeks prior to treatment and for &ge;1 month after treatment.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F5957178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5957179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for serious adverse reactions in the nursing infant, the decision to discontinue bendamustine or discontinue breast-feeding should take into account the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16321818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Treanda Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (1): $606.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (1): $2424.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5957481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential (monitored weekly [initially] in clinical trials); serum creatinine; ALT, AST, and total bilirubin; monitor potassium and uric acid levels in patients at risk for tumor lysis syndrome; monitor for infusion reactions anaphylaxis, infection and dermatologic toxicity; monitor I.V. site during and after infusion.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling also recommends periodic monitoring of blood pressure, serum glucose, and ECG (in patients with cardiac disease particularly if concomitant electrolyte disturbances).",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6875349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Bendit (IN);",
"     </li>",
"     <li>",
"      Levact (BE, CZ, DK, FI, FR, GB, IE, NO);",
"     </li>",
"     <li>",
"      Ribomustin (CH, DE);",
"     </li>",
"     <li>",
"      Symbenda (KP, SG);",
"     </li>",
"     <li>",
"      Treanda (HK)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F5957479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bendamustine is an alkylating agent (nitrogen mustard derivative) with a benzimidazole ring (purine analog) which demonstrates only partial cross-resistance (",
"     <i>",
"      in vitro",
"     </i>",
"     ) with other alkylating agents. It leads to cell death via single and double strand DNA cross-linking. Bendamustine is active against quiescent and dividing cells. The primary cytotoxic activity is due to bendamustine (as compared to metabolites).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F5957371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      ss",
"     </sub>",
"     : ~25 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 94% to 96%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic, via CYP1A2 to active (minor) metabolites gamma-hydroxy bendamustine (M3) and N-desmethyl-bendamustine (M4)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Bendamustine: ~40 minutes; M3: ~3 hours; M4: ~30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, serum: At end of infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Feces (~90%); urine (1% to 10%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aivado M, Schulte K, Henze L, et al, &ldquo;Bendamustine in the Treatment of Chronic Lymphocytic Leukemia: Results and Future Perspectives,&rdquo;",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 2002, 29(4 Suppl 13):19-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/20/32071/abstract-text/12170428/pubmed\" id=\"12170428\" target=\"_blank\">",
"        12170428",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cheson BD, Wendtner CM, Pieper A, et al, &ldquo;Optimal Use of Bendamustine in Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphomas, and Multiple Myeloma: Treatment Recommendations From an International Consensus Panel,&rdquo;",
"      <i>",
"       Clin Lymphoma Myeloma Leuk",
"      </i>",
"      , 2010, 10(1):21-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/20/32071/abstract-text/20223726/pubmed\" id=\"20223726\" target=\"_blank\">",
"        20223726",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dubbelman AC, Rosing H, Darwish M, et al, &ldquo;An Open-Label Phase I Pharmacokinetic Study of [",
"      <sup>",
"       14",
"      </sup>",
"      c] Bendamustine in Patients with Relapsed or Refractory Malignancy,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2011, 118(21):2746 [abstract 2746 from 2011 ASH Annual Meeting]",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fischer K, Cramer P, Busch R, et al, &ldquo;Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2011, 29(26):3559-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/20/32071/abstract-text/21844497/pubmed\" id=\"21844497\" target=\"_blank\">",
"        21844497",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fischer K, Cramer P, Busch R, et al, &ldquo;Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2012, 30(26):3209-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/20/32071/abstract-text/22869884/pubmed\" id=\"22869884\" target=\"_blank\">",
"        22869884",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fowler N, Kahl BS, Lee P, et al, &ldquo;Bortezomib, Bendamustine, and Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma: The Phase II VERTICAL Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2011, 29(25):3389-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/20/32071/abstract-text/21810687/pubmed\" id=\"21810687\" target=\"_blank\">",
"        21810687",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Friedberg JW, Cohen P, Chen L, et al, &ldquo;Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results From a Phase II Multicenter, Single-Agent Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(2):204-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/20/32071/abstract-text/18182663/pubmed\" id=\"18182663\" target=\"_blank\">",
"        18182663",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Friedberg JW, Vose JM, Kelly JL, et al, &ldquo;The Combination of Bendamustine, Bortezomib, and Rituximab for  Patients With Relapsed/Refractory Indolent and Mantle Cell Non-Hodgkin Lymphoma,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2011, 117(10):2807-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/20/32071/abstract-text/21239695/pubmed\" id=\"21239695\" target=\"_blank\">",
"        21239695",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Iannitto E, Morabito F, Mancuso S, et al, &ldquo;Bendamustine With or Without Rituximab in the Treatment of Relapsed Chronic Lymphocytic Leukaemia: An Italian Retrospective Study,&rdquo;",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 2011, 153(3):351-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/20/32071/abstract-text/21371003/pubmed\" id=\"21371003\" target=\"_blank\">",
"        21371003",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kahl BS, Bartlett NL, Leonard JP, et al, &ldquo;Bendamustine Is Effective Therapy in Patients With Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma: Results From a Multicenter Study,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2010, 116(1):106-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/20/32071/abstract-text/19890959/pubmed\" id=\"19890959\" target=\"_blank\">",
"        19890959",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Knauf WU, Lissitchkov T, Aldaoud A, et al, &ldquo;Bendamustine Compared With Chlorambucil In Previously Untreated Patients With Chronic Lymphocytic Leukaemia: Updated Results of a Randomized Phase III Trial,&rdquo;",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 2012, 159(1):67-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/20/32071/abstract-text/22861163/pubmed\" id=\"22861163\" target=\"_blank\">",
"        22861163",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Knauf WU, Lissichkov T, Aldaoud A, et al, &ldquo;Phase III Randomized Study of Bendamustine Compared With Chlorambucil in Previously Untreated Patients With Chronic Lymphocytic Leukemia (B-CLL),&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(26):4378-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/20/32071/abstract-text/19652068/pubmed\" id=\"19652068\" target=\"_blank\">",
"        19652068",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Knop S, Straka C, Haen M, et al, &ldquo;The Efficacy and Toxicity of Bendamustine in Recurrent Multiple Myeloma After High-Dose Chemotherapy,&rdquo;",
"      <i>",
"       Haematologica",
"      </i>",
"      , 2005, 90(9):1287-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/20/32071/abstract-text/16154860/pubmed\" id=\"16154860\" target=\"_blank\">",
"        16154860",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Michael M, Bruns I, B&ouml;lke E, et al, &ldquo;Bendamustine in Patients With Relapsed or Refractory Multiple Myeloma,&rdquo;",
"      <i>",
"       Eur J Med Res",
"      </i>",
"      , 2010, 15(1):13-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/20/32071/abstract-text/20159666/pubmed\" id=\"20159666\" target=\"_blank\">",
"        20159666",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moskowitz, AJ, Hamlin PA, Gerecitano J, et al, &ldquo;Bendamustine is Highly Active in Heavily Pre-Treated Relapsed and Refractory Hodgkin Lymphoma and Serves as a Bridge to Allogeneic Stem Cell Transplant,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2009, 114(22):720 [abstract 720 from 2009 ASH Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nordstrom BL, Knopf KB, Teltsch D, et al, &ldquo;Retrospective safety assessment of bendamustine in patients with renal impairment,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2012, 30(15s):e13018 [abstract e13018 from 2012 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Owen JS, Melhem M, Passarell JA, et al, &ldquo;Bendamustine Pharmacokinetic Profile and Exposure-Response Relationships in Patients With Indolent Non-Hodgkin's Lymphoma,&rdquo;",
"      <i>",
"       Cancer Chemother Pharmacol",
"      </i>",
"      , 2010, 66(6):1039-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/20/32071/abstract-text/20140617/pubmed\" id=\"20140617\" target=\"_blank\">",
"        20140617",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      P&eacute;rez Fidalgo JA, Garc&iacute;a Fabregat L, Cervantes A, et al, &ldquo;Management of Chemotherapy Extravasation: ESMO-EONS Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2012, 23(Suppl 7):167-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/20/32071/abstract-text/22997449/pubmed\" id=\"22997449\" target=\"_blank\">",
"        22997449",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ponisch W and Niederwieser D, &ldquo;Bendamustine in the Treatment of Multiple Myeloma: Results and Future Perspectives,&rdquo;",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 2002, 29(4 Suppl 13):23-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/20/32071/abstract-text/12170429/pubmed\" id=\"12170429\" target=\"_blank\">",
"        12170429",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Robinson KS, Williams ME, van der Jagt RH, et al, &ldquo;Phase II Multicenter Study of Bendamustine Plus Rituximab in Patients With Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin's Lymphoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(27):4473-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/20/32071/abstract-text/18626004/pubmed\" id=\"18626004\" target=\"_blank\">",
"        18626004",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rummel MJ, Al-Batran SE, Kim SZ, et al, &ldquo;Bendamustine Plus Rituximab is Effective and has a Favorable Toxicity Profile in the Treatment of Mantle Cell and Low-Grade Non-Hodgkin's Lymphoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(15):3383-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/20/32071/abstract-text/15908650/pubmed\" id=\"15908650\" target=\"_blank\">",
"        15908650",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rummel MJ, Niederle N, Maschmeyer G, et al, &ldquo;Bendamustine Plus Rituximab (B-R) versus CHOP Plus Rituximab (CHOP-R) as First-Line Treatment in Patients With Indolent and Mantle Cell Lymphomas (MCL): Updated Results From the StiL NHL1 Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2012, 30(15s):3 [abstract 3 from 2012 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rummel MJ, Niederle N, Maschmeyer G, et al, &ldquo;Bendamustine Plus Rituximab is Superior in Respect of Progression Free Survival and CR Rate When Compared to CHOP Plus Rituximab as First-Line Treatment of Patients With Advanced Follicular, Indolent, and Mantle Cell Lymphomas: Final Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany),&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2009, 114(22):405 [abstract 405 from 2009 ASH Annual Meeting]",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tapan U, May SK, Fiore J, et al, &ldquo;Reactivation of Hepatitis B Virus Following Bendamustine-Containing Chemotherapy in a Patient With Multiple Myeloma,&rdquo;",
"      <i>",
"       Leuk Lymphoma",
"      </i>",
"      , 2011, 52(5):916-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/20/32071/abstract-text/21306291/pubmed\" id=\"21306291\" target=\"_blank\">",
"        21306291",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Teichert J, Baumann F, Chao Q, et al, &ldquo;Characterization of Two Phase I Metabolites of Bendamustine in Human Liver Microsomes and in Cancer Patients Treated With Bendamustine Hydrochloride,&rdquo;",
"      <i>",
"       Cancer Chemother Pharmacol",
"      </i>",
"      , 2007, 59(6):759-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/20/32071/abstract-text/16957931/pubmed\" id=\"16957931\" target=\"_blank\">",
"        16957931",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Teichert J, Sohr R, Baumann F, et al, &ldquo;Synthesis and Characterization of Some New Phase II Metabolites of the Alkylator Bendamustine and Their Identification in Human Bile, Urine, and Plasma From Patients With Cholangiocarcinoma,&rdquo;",
"      <i>",
"       Drug Metab Dispos",
"      </i>",
"      , 2005, 33(7):984-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/20/32071/abstract-text/15845750/pubmed\" id=\"15845750\" target=\"_blank\">",
"        15845750",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Treon SP, Hanzis C, Tripsas C, et al, &ldquo;Bendamustine Therapy in Patients With Relapsed or Refractory Waldenstr&ouml;m's Macroglobulinemia,&rdquo;",
"      <i>",
"       Clin Lymphoma Myeloma Leuk",
"      </i>",
"      , 2011, 11(1):133-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/20/32071/abstract-text/21454214/pubmed\" id=\"21454214\" target=\"_blank\">",
"        21454214",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9323 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-202.43.93.2-481E12C6DB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_20_32071=[""].join("\n");
var outline_f31_20_32071=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5957167\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15065726\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5957171\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5958743\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5957380\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5957381\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5957382\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5957403\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5957484\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5957169\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5957404\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5957370\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5957173\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5957174\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5957165\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5957206\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5957180\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5957181\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5957266\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5957265\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5957175\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5957176\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5957178\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5957179\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16321818\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5957481\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6875349\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5957479\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5957371\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9323\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9323|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/55/41844?source=related_link\">",
"      Bendamustine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_20_32072="Systemic treatment for metastatic breast cancer: Selection of chemotherapy regimen";
var content_f31_20_32072=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Systemic treatment for metastatic breast cancer: Selection of chemotherapy regimen",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/20/32072/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/20/32072/contributors\">",
"     Daniel F Hayes, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/20/32072/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/20/32072/contributors\">",
"     Julie R Gralow, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/20/32072/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/20/32072/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?31/20/32072/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H691733523\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although metastatic breast cancer is unlikely to be cured, meaningful improvements in survival have been seen, coincident with the introduction of newer systemic therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32072/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Median overall survival approaches two years, with a range from a few months to many years [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32072/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The selection of a therapeutic strategy depends upon both tumor biology and clinical factors, with the goal being a tailored approach. Although a subset of patients with oligometastatic disease may benefit from an intensified locoregional approach, most patients with metastatic breast cancer receive systemic medical therapy, consisting of chemotherapy, endocrine therapy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    biologic therapies, and supportive care measures [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32072/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Principles in selecting a chemotherapy regimen are presented here. Active single agent and combination chemotherapy regimens, including biologic therapies, are discussed separately, as are endocrine therapy and supportive care.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7354?source=see_link\">",
"       \"Systemic treatment for metastatic breast cancer: General principles\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/55/21370?source=see_link\">",
"       \"Treatment approach to metastatic hormone receptor-positive breast cancer: Endocrine therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/27/11705?source=see_link\">",
"       \"Systemic treatment for metastatic breast cancer: Combination chemotherapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29528?source=see_link\">",
"       \"Systemic treatment for metastatic breast cancer: Single agent chemotherapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22202?source=see_link\">",
"       \"Systemic treatment for metastatic breast cancer: Molecular targeted therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40903?source=see_link\">",
"       \"Treatment of metastatic breast cancer in older women\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90130530\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The selection of chemotherapy for metastatic breast cancer must be individualized and balance disease-related factors, such as disease sites, apparent progression rate, and hormone receptor and human epidermal growth factor receptor 2 (HER2) status, with patient factors, such as comorbidities and general health. Response and resistance to prior chemotherapy, as well as prior therapy-related toxicities, should also be taken into account.",
"   </p>",
"   <p>",
"    Principles for the use of chemotherapy in metastatic breast cancer, although discussed separately, are outlined here. &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment gains in disease response and survival must be balanced with effects on quality of life and tolerability.",
"     </li>",
"     <li>",
"      Chemotherapy is indicated for patients with hormone-insensitive metastatic breast cancer (ie, patients with hormone-receptor-negative breast cancer and those with hormone receptor-positive breast cancer who have become resistant to endocrine therapy) or for those with hormone receptor-positive breast cancer and an aggressive phenotype (ie, visceral crisis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a short disease-free interval).",
"     </li>",
"     <li>",
"      Human epidermal growth factor receptor 2 (HER2)-directed therapy has demonstrated improved survival for patients with tumors that overexpress HER2 and thus should be part of first-line therapy for these patients.",
"     </li>",
"     <li>",
"      Chemotherapy can be given singly or in combination. Without an appreciable survival advantage with combination chemotherapy, sequential therapy with single agents is often preferred. Toxicity is less with single agent therapy and quality of life appears better. However, combination therapy may be a more appropriate first-line choice for symptomatic patients or those with rapidly progressive visceral metastases because of the greater likelihood of an objective response.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The aims and indications for systemic therapy, including chemotherapy, endocrine therapy, and biologic (molecularly targeted) therapy and general principles in selecting and monitoring systemic treatment for metastatic breast cancer, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7354?source=see_link\">",
"     \"Systemic treatment for metastatic breast cancer: General principles\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H691733544\">",
"    <span class=\"h2\">",
"     Prior chemotherapy exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selection of chemotherapy depends upon prior chemotherapy exposure, whether as neoadjuvant or adjuvant therapy or previous treatment for metastatic disease. Prior chemotherapy exposure impacts upon response rates and risks for toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32072/abstract/7\">",
"     7",
"    </a>",
"    ]. An interval of 12 months between initial use of an agent in the adjuvant setting and the time of relapse or progression is typically used to define chemotherapy sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32072/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with previous response to a taxane, rechallenging with a taxane is an option since",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    do not show complete cross-resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32072/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29528?source=see_link&amp;anchor=H84529057#H84529057\">",
"     \"Systemic treatment for metastatic breast cancer: Single agent chemotherapy\", section on 'Taxanes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is also a role for rechallenging with anthracyclines in select patients; however, as discussed below, the repeated use of anthracyclines is limited by the risk for anthracycline cardiotoxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H691733551\">",
"    <span class=\"h3\">",
"     Anthracycline cardiotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anthracycline-related cardiotoxicity is characterized by a cumulative and dose-related progressive myocardial damage. Clinical features range from an asymptomatic reduction in left ventricular ejection fraction to irreversible, life-threatening heart failure. The incidence of cardiotoxicity is directly related to cumulative total dose, increasing sharply for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    doses above 450",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=see_link\">",
"     \"Cardiotoxicity of anthracycline-like chemotherapy agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to cumulative anthracycline dose, it is also important to consider other factors that increase cardiovascular vulnerability, including previous radiation therapy, other chemotherapy and biological agents with adverse effects on the cardiovascular system (particularly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    ), and preexisting cardiovascular risk factors such as age, obesity, physical inactivity, hypertension, smoking, diabetes, and hyperlipidemia [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32072/abstract/10\">",
"     10",
"    </a>",
"    ]. It may be appropriate to assess and treat patients for modifiable risk factors, such as angiotensin-converting enzyme inhibitors in patients with hypertension.",
"   </p>",
"   <p>",
"    It is feasible to consider retreatment with anthracyclines for metastatic disease, as long as the cumulative anthracycline dose is limited (450 to 550",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    and 800 to 1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32072/abstract/9,11\">",
"     9,11",
"    </a>",
"    ]. The risk of cardiotoxicity may be reduced by lower doses given weekly (such as 20",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ),",
"    </span>",
"    prolonged doxorubicin infusion time,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/13/10458?source=see_link\">",
"     liposomal doxorubicin",
"    </a>",
"    preparations, and administration of the cardioprotectant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/28/30150?source=see_link\">",
"     dexrazoxane",
"    </a>",
"    . Epirubicin and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"     mitoxantrone",
"    </a>",
"    are less cardiotoxic than doxorubicin on a",
"    <span class=\"nowrap\">",
"     mg/mg",
"    </span>",
"    basis. However, since they are also less potent than doxorubicin on a mg per mg basis, any cardiotoxicity advantage may be negated by the higher doses [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32072/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29528?source=see_link&amp;anchor=H84534185#H84534185\">",
"     \"Systemic treatment for metastatic breast cancer: Single agent chemotherapy\", section on 'Anthracyclines'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90130492\">",
"    <span class=\"h2\">",
"     Order of administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there is no clearly defined optimal first-line regimen, some patients with particularly aggressive or symptomatic disease may benefit from combination chemotherapy regimens or single agents with higher response rates. Response rates for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    are higher as first&ndash;line therapy than when administered as cross-over after progression on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    (41 versus 30 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32072/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"     Anthracycline/taxane",
"    </span>",
"    combinations, including",
"    <span class=\"nowrap\">",
"     doxorubicin/paclitaxel",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     doxorubicin/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"      docetaxel",
"     </a>",
"    </span>",
"    (both AT), have high overall response rates and improved progression-free survival when compared to non-taxane anthracycline combinations, but also significant toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32072/abstract/15\">",
"     15",
"    </a>",
"    ]. Nevertheless, overall survival does not appear to be significantly affected by the order of administration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H691733565\">",
"    <span class=\"h2\">",
"     Treatment duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal duration of chemotherapy for metastatic breast cancer is debated. Trials of extended duration therapy have demonstrated improved progression-free survival, but no overall survival benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32072/abstract/16-22\">",
"     16-22",
"    </a>",
"    ]. Additional cycles of chemotherapy are often associated with a significant increase in toxicity and decreased quality of life. Clinical practice varies, with some clinicians treating for four or six months then stopping, and others treating to best response or progressive disease, as long as treatment is reasonably well tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32072/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The issue of duration of first-line chemotherapy was addressed in a meta-analysis of published data from 11 trials (2269 patients) in which patients were randomly assigned to longer versus shorter duration of chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32072/abstract/22\">",
"     22",
"    </a>",
"    ]. The trial designs were heterogeneous but most compared a fixed number of courses of therapy versus treatment until disease progression. Longer duration chemotherapy was associated with a statistically significant 36 percent reduction in the risk of progression, and a significant 9 percent reduction in the risk of death. &nbsp;",
"   </p>",
"   <p>",
"    While these data argue in favor of longer duration of first-line chemotherapy, there is no &ldquo;one size fits all&rdquo; approach that suits all patients. In practice, one approach is to treat patients with hormone receptor-positive or HER2-positive breast cancer with a fixed number of cycles of cytotoxic chemotherapy, followed by an attempt at disease maintenance with the endocrine agent or HER2-directed therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32072/abstract/23\">",
"     23",
"    </a>",
"    ]. Treatment with chemotherapy can then be then resumed upon disease progression.",
"   </p>",
"   <p>",
"    For patients who have tumors that are negative for hormone receptors or HER2, for which chemotherapy is the primary treatment option, the risks and benefits of continued chemotherapy need to be assessed periodically during treatment. While continued chemotherapy until disease progression may maximize oncologic outcomes, treatment-related toxicities and quality of life can become more difficult to manage over time and may influence the decision as to treatment duration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5330704\">",
"    <span class=\"h1\">",
"     ACTIVE CHEMOTHERAPY REGIMENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some preferred regimens are as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32072/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <strong>",
"     Anthracyclines",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       Doxorubicin",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"       Epirubicin",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/13/10458?source=see_link\">",
"       Pegylated liposomal doxorubicin",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"       Mitoxantrone",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Taxanes",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       Paclitaxel",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"       Docetaxel",
"      </a>",
"     </li>",
"     <li>",
"      Albumin-bound",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Anti-metabolites",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"       Capecitabine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       Gemcitabine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/27/36279?source=see_link\">",
"       Pemetrexed",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Other single agents",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/42/28325?source=see_link\">",
"       Eribulin",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       Etoposide",
"      </a>",
"      orally",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       Cyclophosphamide",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       Cisplatin",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"       Fluorouracil",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/11/10423?source=see_link\">",
"       Ixabepilone",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"       Irinotecan",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/59/953?source=see_link\">",
"       Vinorelbine",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Chemotherapy combinations",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       CAF/FAC",
"      </span>",
"      <span class=\"nowrap\">",
"       (",
"       <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"        cyclophosphamide",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"        doxorubicin",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"        fluorouracil",
"       </a>",
"       )",
"      </span>",
"     </li>",
"     <li>",
"      FEC",
"      <span class=\"nowrap\">",
"       (",
"       <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"        fluorouracil",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"        epirubicin",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"        cyclophosphamide",
"       </a>",
"       )",
"      </span>",
"     </li>",
"     <li>",
"      AC",
"      <span class=\"nowrap\">",
"       (",
"       <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"        doxorubicin",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"        cyclophosphamide",
"       </a>",
"       )",
"      </span>",
"     </li>",
"     <li>",
"      EC",
"      <span class=\"nowrap\">",
"       (",
"       <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"        epirubicin",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"        cyclophosphamide",
"       </a>",
"       )",
"      </span>",
"     </li>",
"     <li>",
"      AT",
"      <span class=\"nowrap\">",
"       (",
"       <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"        doxorubicin",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"        docetaxel",
"       </a>",
"       ;",
"      </span>",
"      <span class=\"nowrap\">",
"       doxorubicin/",
"       <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"        paclitaxel",
"       </a>",
"       )",
"      </span>",
"     </li>",
"     <li>",
"      CMF",
"      <span class=\"nowrap\">",
"       (",
"       <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"        cyclophosphamide",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"        methotrexate",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"        fluorouracil",
"       </a>",
"       )",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"        Docetaxel",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"        capecitabine",
"       </a>",
"      </span>",
"     </li>",
"     <li>",
"      GT",
"      <span class=\"nowrap\">",
"       (",
"       <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"        gemcitabine",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"        paclitaxel",
"       </a>",
"       )",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?10/11/10423?source=see_link\">",
"        Ixabepilone",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"        capecitabine",
"       </a>",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Biologic agents",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       Bevacizumab",
"      </a>",
"      with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     HER2-positive disease",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       Trastuzumab",
"      </a>",
"      with:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       Paclitaxel",
"      </a>",
"      with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"       Docetaxel",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/59/953?source=see_link\">",
"       Vinorelbine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"       Capecitabine",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/23/9592?source=see_link\">",
"       Lapatinib",
"      </a>",
"      with:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"       Capecitabine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       Paclitaxel",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       Trastuzumab",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Details on the use of these chemotherapy regimens are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29528?source=see_link\">",
"       \"Systemic treatment for metastatic breast cancer: Single agent chemotherapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/27/11705?source=see_link\">",
"       \"Systemic treatment for metastatic breast cancer: Combination chemotherapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22202?source=see_link\">",
"       \"Systemic treatment for metastatic breast cancer: Molecular targeted therapy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90130523\">",
"    <span class=\"h1\">",
"     FIRST-LINE TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;First-line treatment for metastatic breast cancer is likely to result in a reasonable chance (30 to 60 percent) of response, successful symptom palliation, and improved quality of life, regardless of the regimen chosen. There is no clearly identified first-line regimen for metastatic breast cancer. Furthermore, as described above, there is no clear advantage in overall survival for combination chemotherapy compared to sequential single agents. For most patients, we prefer sequential single agent therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7354?source=see_link&amp;anchor=H129020#H129020\">",
"     \"Systemic treatment for metastatic breast cancer: General principles\", section on 'Sequential single agents versus combination chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients who are anthracycline na&iuml;ve or who develop metastases more than 12 months after anthracycline-based adjuvant therapy, we and others recommend anthracyclines as first-line therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32072/abstract/6,25,26\">",
"     6,25,26",
"    </a>",
"    ]. An alternative in taxane-na&iuml;ve patients is single-agent taxanes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29528?source=see_link&amp;anchor=H89090299#H89090299\">",
"     \"Systemic treatment for metastatic breast cancer: Single agent chemotherapy\", section on 'Taxanes versus anthracyclines'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Common dosing schedules for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    are doxorubicin (60 to 75",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every three weeks or 20",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    weekly) and epirubicin (75 to 100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every three weeks or 20 to 30",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    weekly). Both liposome-encapsulated and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/13/10458?source=see_link\">",
"     pegylated liposomal doxorubicin",
"    </a>",
"    have demonstrated comparable efficacy to doxorubicin, but with reduced cardiotoxicity, and thus may be good options for patients with preexisting cardiac disease or in those who are near the cumulative cardiotoxicity threshold. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29528?source=see_link&amp;anchor=H84534185#H84534185\">",
"     \"Systemic treatment for metastatic breast cancer: Single agent chemotherapy\", section on 'Anthracyclines'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Combinations of anthracyclines plus a taxane are associated with very high response rates, but these combinations are more toxic than sequential use of single agents, and their impact on survival is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32072/abstract/25\">",
"     25",
"    </a>",
"    ]. They may be appropriate first-line therapy for a patient with rapidly progressive",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    symptomatic visceral disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/27/11705?source=see_link&amp;anchor=H26024911#H26024911\">",
"     \"Systemic treatment for metastatic breast cancer: Combination chemotherapy\", section on 'Anthracycline-based regimens'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/27/11705?source=see_link&amp;anchor=H26026452#H26026452\">",
"     \"Systemic treatment for metastatic breast cancer: Combination chemotherapy\", section on 'Anthracycline/taxane combinations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     Bevacizumab",
"    </a>",
"    in combination with weekly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    is a reasonable option for initial treatment for patients with human epidermal growth factor receptor 2 (HER2)-negative disease. However, the utility of bevacizumab in the treatment of metastatic breast cancer and its",
"    <span class=\"nowrap\">",
"     risk/benefit",
"    </span>",
"    ratio is an area of controversy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22202?source=see_link&amp;anchor=H111524024#H111524024\">",
"     \"Systemic treatment for metastatic breast cancer: Molecular targeted therapy\", section on 'Vascular Endothelial Growth Factor Receptor Inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For elderly women and those with a borderline performance status, single agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/59/953?source=see_link\">",
"     vinorelbine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    is a reasonable first-line alternative to an anthracycline or a taxane.",
"   </p>",
"   <p>",
"    The frequent use of anthracyclines and taxanes in the adjuvant setting limits their use with metastatic disease, and alternatives in anthracycline-",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    taxane-pretreated patients are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111514912\">",
"    <span class=\"h1\">",
"     CHEMOTHERAPY AFTER ANTHRACYCLINE-PRETREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Taxanes have comparable activity to anthracyclines in metastatic breast cancer, and so it follows that the taxanes, either as single agents or in combination, are commonly used in patients previously exposed to anthracyclines [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32072/abstract/27\">",
"     27",
"    </a>",
"    ]. Options include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    dosed weekly,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    every three weeks, and nab-paclitaxel. Neither docetaxel nor nab-paclitaxel has demonstrated superiority over weekly paclitaxel. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29528?source=see_link&amp;anchor=H84529057#H84529057\">",
"     \"Systemic treatment for metastatic breast cancer: Single agent chemotherapy\", section on 'Taxanes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is unclear whether taxane combinations are any more effective than single agent taxanes. Although some studies have suggested that combination therapy is superior to single agent taxane, others found weekly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    to be superior to taxane combinations (both paclitaxel and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/27/11705?source=see_link&amp;anchor=H26026459#H26026459\">",
"     \"Systemic treatment for metastatic breast cancer: Combination chemotherapy\", section on 'Nonanthracycline taxane combinations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is feasible to consider retreatment with anthracycline, as long as the cumulative anthracycline dose is limited (450 to 550",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    and 800 to 1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H691733551\">",
"     'Anthracycline cardiotoxicity'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29528?source=see_link&amp;anchor=H84534185#H84534185\">",
"     \"Systemic treatment for metastatic breast cancer: Single agent chemotherapy\", section on 'Anthracyclines'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111514982\">",
"    <span class=\"h1\">",
"     CHEMOTHERAPY AFTER ANTHRACYCLINE AND TAXANE PRETREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with prior exposure to anthracyclines and taxanes,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    is commonly used given its efficacy and ease of administration. Other options include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/59/953?source=see_link\">",
"     vinorelbine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/42/28325?source=see_link\">",
"     eribulin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/11/10423?source=see_link\">",
"     ixabepilone",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29528?source=see_link&amp;anchor=H780566854#H780566854\">",
"     \"Systemic treatment for metastatic breast cancer: Single agent chemotherapy\", section on 'Active chemotherapy agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with previous response to a taxane, rechallenging with a taxane is an option since",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    do not show complete cross-resistance. (See",
"    <a class=\"local\" href=\"#H691733544\">",
"     'Prior chemotherapy exposure'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29528?source=see_link&amp;anchor=H84529057#H84529057\">",
"     \"Systemic treatment for metastatic breast cancer: Single agent chemotherapy\", section on 'Taxanes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H180379\">",
"    <span class=\"h1\">",
"     HER2-POSITIVE BREAST CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend that patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer receive HER2-directed therapy as first-line treatment. The use of HER2-directed therapies in metastatic breast cancer is reviewed in detail separately, including HER2-directed",
"    <span class=\"nowrap\">",
"     therapy/chemotherapy",
"    </span>",
"    combinations and HER2-directed",
"    <span class=\"nowrap\">",
"     therapy/endocrine",
"    </span>",
"    therapy combinations.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22202?source=see_link&amp;anchor=H111523989#H111523989\">",
"       \"Systemic treatment for metastatic breast cancer: Molecular targeted therapy\", section on 'HER2-directed therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/55/21370?source=see_link&amp;anchor=H19266990#H19266990\">",
"       \"Treatment approach to metastatic hormone receptor-positive breast cancer: Endocrine therapy\", section on 'HER2-positive breast cancer'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    has demonstrated both efficacy and safety when combined with a wide variety of chemotherapy agents, the choice of chemotherapy is similar to that described above for patients with HER2-negative disease. The exception is anthracyclines, which result in increased cardiac toxicity when given in combination with trastuzumab. &nbsp;As first line treatment,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/23/9592?source=see_link\">",
"     lapatinib",
"    </a>",
"    has not been compared with trastuzumab and is most commonly used upon trastuzumab progression.",
"   </p>",
"   <p>",
"    Anthracyclines are good options for HER2-positive breast cancer that has become resistant to HER2-directed therapy.",
"   </p>",
"   <p>",
"    The issue of continuation of HER2-targeted therapy with the second-line regimen in patients with HER2-positive disease who are initially treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    is controversial and is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22202?source=see_link&amp;anchor=H111525572#H111525572\">",
"     \"Systemic treatment for metastatic breast cancer: Molecular targeted therapy\", section on 'Second or later line treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H180372\">",
"    <span class=\"h1\">",
"     TRIPLE-NEGATIVE BREAST CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemotherapy remains the primary therapy for metastatic triple-negative breast cancer (both hormone receptor-negative and HER2-negative), but optimal chemotherapy regimens have not been defined. Triple-negative breast cancer, especially if associated with a breast cancer 1 (BRCA1) mutation, may have particular sensitivity to certain chemotherapy agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/42/28325?source=see_link\">",
"     eribulin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/11/10423?source=see_link\">",
"     ixabepilone",
"    </a>",
"    , as well as the targeted agents, poly(ADP)ribose polymerase 1 (PARP1) inhibitors and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32072/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/40/34441?source=see_link&amp;anchor=H1136598543#H1136598543\">",
"     \"Epidemiology, risk factors and the clinical approach to ER/PR negative, HER2-negative (Triple-negative) breast cancer\", section on 'Metastatic disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/11/27827?source=see_link\">",
"       \"Patient information: Treatment of metastatic breast cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H691732105\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no \"one size fits all\" approach to selecting chemotherapy treatment for patients with metastatic breast cancer.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest sequential single agent chemotherapy for most patients with metastatic breast cancer who require chemotherapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Combination chemotherapy may be preferable for selected patients with rapidly progressive disease, visceral crisis, or if quick symptom control is desired. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7354?source=see_link&amp;anchor=H129020#H129020\">",
"       \"Systemic treatment for metastatic breast cancer: General principles\", section on 'Sequential single agents versus combination chemotherapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      First-line treatment of metastatic breast cancer is likely to result in a reasonable chance (30 to 60 percent) of response, successful symptom palliation, and improved quality of life, regardless of the regimen chosen. (See",
"      <a class=\"local\" href=\"#H90130523\">",
"       'First-line treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Single agent anthracyclines are commonly used as first-line treatment in anthracycline-naive patients.",
"     </li>",
"     <li>",
"      Taxanes, either as single agents or in combination, are commonly used in patients previously exposed to anthracyclines, or those who have relapsed after at least a year after adjuvant taxane exposure.",
"     </li>",
"     <li>",
"      For patients previously exposed to anthracyclines and taxanes,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      is commonly used given its efficacy and ease of administration. Other options include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/59/953?source=see_link\">",
"       vinorelbine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/42/28325?source=see_link\">",
"       eribulin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/11/10423?source=see_link\">",
"       ixabepilone",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      It is feasible to consider retreatment with anthracyclines for metastatic disease, as long as the cumulative anthracycline dose is limited (450 to 550",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      and 800 to 1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"       epirubicin",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H691733551\">",
"       'Anthracycline cardiotoxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with previous response to a taxane, rechallenging with an alternative taxane is an option since",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      do not show complete cross-resistance. (See",
"      <a class=\"local\" href=\"#H691733544\">",
"       'Prior chemotherapy exposure'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer receive HER2-directed therapy as first-line treatment (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22202?source=see_link&amp;anchor=H111523989#H111523989\">",
"       \"Systemic treatment for metastatic breast cancer: Molecular targeted therapy\", section on 'HER2-directed therapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       Trastuzumab",
"      </a>",
"      plus a conventional cytotoxic agent, frequently a taxane, is commonly used as first-line treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The optimal duration of first-line chemotherapy for metastatic breast cancer is debated, and there is no single approach that is suitable for all patients. We favor the following approach (see",
"      <a class=\"local\" href=\"#H691733565\">",
"       'Treatment duration'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients who have hormone receptor-positive or HER2-positive disease, one approach is to treat patients with a fixed number of cycles of cytotoxic chemotherapy, followed by an attempt at disease maintenance with the endocrine agent or HER2-directed therapy. Treatment with chemotherapy can then be then resumed upon disease progression.",
"     </li>",
"     <li>",
"      For patients who have tumors that are negative for hormone receptors or HER2, for which chemotherapy is the primary treatment option, the risks and benefits of continued chemotherapy need to be assessed periodically during treatment. While continued chemotherapy until disease progression may maximize oncologic outcomes, treatment-related toxicities and quality of life may influence the decision as to treatment duration.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32072/abstract/1\">",
"      Chia SK, Speers CH, D'yachkova Y, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 2007; 110:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32072/abstract/2\">",
"      Gennari A, Conte P, Rosso R, et al. Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer 2005; 104:1742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32072/abstract/3\">",
"      Dafni U, Grimani I, Xyrafas A, et al. Fifteen-year trends in metastatic breast cancer survival in Greece. Breast Cancer Res Treat 2010; 119:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32072/abstract/4\">",
"      Greenberg PA, Hortobagyi GN, Smith TL, et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14:2197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32072/abstract/5\">",
"      Pagani O, Senkus E, Wood W, et al. International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? J Natl Cancer Inst 2010; 102:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32072/abstract/6\">",
"      Beslija S, Bonneterre J, Burstein HJ, et al. Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 2009; 20:1771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32072/abstract/7\">",
"      Nabholtz JM, Gelmon K, Bontenbal M, et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 1996; 14:1858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32072/abstract/8\">",
"      Valagussa P, Tancini G, Bonadonna G. Salvage treatment of patients suffering relapse after adjuvant CMF chemotherapy. Cancer 1986; 58:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32072/abstract/9\">",
"      Palmieri C, Krell J, James CR, et al. Rechallenging with anthracyclines and taxanes in metastatic breast cancer. Nat Rev Clin Oncol 2010; 7:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32072/abstract/10\">",
"      Barrett-Lee PJ, Dixon JM, Farrell C, et al. Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. Ann Oncol 2009; 20:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32072/abstract/11\">",
"      Al-Batran SE, G&uuml;ntner M, Pauligk C, et al. Anthracycline rechallenge using pegylated liposomal doxorubicin in patients with metastatic breast cancer: a pooled analysis using individual data from four prospective trials. Br J Cancer 2010; 103:1518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32072/abstract/12\">",
"      van Dalen EC, Michiels EM, Caron HN, Kremer LC. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev 2006; :CD005006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32072/abstract/13\">",
"      Henderson IC, Allegra JC, Woodcock T, et al. Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol 1989; 7:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32072/abstract/14\">",
"      Paridaens R, Biganzoli L, Bruning P, et al. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol 2000; 18:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32072/abstract/15\">",
"      Piccart-Gebhart MJ, Burzykowski T, Buyse M, et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol 2008; 26:1980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32072/abstract/16\">",
"      Muss HB, Case LD, Richards F 2nd, et al. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. N Engl J Med 1991; 325:1342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32072/abstract/17\">",
"      Cocconi G, Bisagni G, Bacchi M, et al. A comparison of continuation versus late intensification followed by discontinuation of chemotherapy in advanced breast cancer. A prospective randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.). Ann Oncol 1990; 1:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32072/abstract/18\">",
"      Gennari A, Amadori D, De Lena M, et al. Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer. J Clin Oncol 2006; 24:3912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32072/abstract/19\">",
"      Falkson G, Gelman RS, Pandya KJ, et al. Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. J Clin Oncol 1998; 16:1669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32072/abstract/20\">",
"      Gregory RK, Powles TJ, Chang JC, Ashley S. A randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast. Eur J Cancer 1997; 33:2194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32072/abstract/21\">",
"      Alba E, Ruiz-Borrego M, Margel&iacute; M, et al. Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study. Breast Cancer Res Treat 2010; 122:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32072/abstract/22\">",
"      Gennari A, Stockler M, Puntoni M, et al. Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. J Clin Oncol 2011; 29:2144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32072/abstract/23\">",
"      Seidman AD. How long is long enough? J Clin Oncol 2011; 29:2129.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology are available online at file://www.nccn.org/professionals/physician_gls/f_guidelines.asp (Accessed on July 28, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32072/abstract/25\">",
"      Cardoso F, Bedard PL, Winer EP, et al. International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst 2009; 101:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32072/abstract/26\">",
"      Andreetta C, Minisini AM, Miscoria M, Puglisi F. First-line chemotherapy with or without biologic agents for metastatic breast cancer. Crit Rev Oncol Hematol 2010; 76:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32072/abstract/27\">",
"      Ghersi D, Wilcken N, Simes RJ. A systematic review of taxane-containing regimens for metastatic breast cancer. Br J Cancer 2005; 93:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32072/abstract/28\">",
"      Santana-Davila R, Perez EA. Treatment options for patients with triple-negative breast cancer. J Hematol Oncol 2010; 3:42.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15543 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-A93D27A9D4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_20_32072=[""].join("\n");
var outline_f31_20_32072=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H691732105\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H691733523\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H90130530\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H691733544\">",
"      Prior chemotherapy exposure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H691733551\">",
"      - Anthracycline cardiotoxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H90130492\">",
"      Order of administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H691733565\">",
"      Treatment duration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5330704\">",
"      ACTIVE CHEMOTHERAPY REGIMENS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H90130523\">",
"      FIRST-LINE TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H111514912\">",
"      CHEMOTHERAPY AFTER ANTHRACYCLINE-PRETREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H111514982\">",
"      CHEMOTHERAPY AFTER ANTHRACYCLINE AND TAXANE PRETREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H180379\">",
"      HER2-POSITIVE BREAST CANCER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H180372\">",
"      TRIPLE-NEGATIVE BREAST CANCER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H691732105\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=related_link\">",
"      Cardiotoxicity of anthracycline-like chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/40/34441?source=related_link\">",
"      Epidemiology, risk factors and the clinical approach to ER/PR negative, HER2-negative (Triple-negative) breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/11/27827?source=related_link\">",
"      Patient information: Treatment of metastatic breast cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/27/11705?source=related_link\">",
"      Systemic treatment for metastatic breast cancer: Combination chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7354?source=related_link\">",
"      Systemic treatment for metastatic breast cancer: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22202?source=related_link\">",
"      Systemic treatment for metastatic breast cancer: Molecular targeted therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29528?source=related_link\">",
"      Systemic treatment for metastatic breast cancer: Single agent chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/55/21370?source=related_link\">",
"      Treatment approach to metastatic hormone receptor-positive breast cancer: Endocrine therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40903?source=related_link\">",
"      Treatment of metastatic breast cancer in older women",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_20_32073="Total joint replacement for severe rheumatoid arthritis";
var content_f31_20_32073=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Total joint replacement for severe rheumatoid arthritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/20/32073/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/20/32073/contributors\">",
"     Michael H Weisman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/20/32073/contributors\">",
"     Renee Z Rinaldi, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/20/32073/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/20/32073/contributors\">",
"     RN Maini, BA, MB BChir, FRCP, FMedSci, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/20/32073/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/20/32073/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?31/20/32073/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rheumatoid arthritis (RA) is a chronic, progressive disorder in many patients. Despite therapy with disease-modifying antirheumatic drugs (DMARDS), including biologic agents, joint erosion and destruction can develop over time. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=see_link\">",
"     \"General principles of management of rheumatoid arthritis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The major symptom of joint destruction is pain. With further progression of the arthritis, there are signs of loss of motion, diminution in motor strength, and, ultimately, decline in function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37861?source=see_link\">",
"     \"Evaluation and medical management of end-stage rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the surgical indications, procedures, management approach, and complications of total joint replacement in patients with severe rheumatoid arthritis. Overviews of total hip and knee arthroplasty and their complications, as well as the perioperative management of patients with rheumatic diseases, are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10106?source=see_link\">",
"     \"Total hip arthroplasty\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/6/17514?source=see_link\">",
"     \"Total knee arthroplasty\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/39/1658?source=see_link\">",
"     \"Complications of total hip arthroplasty\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/32/16902?source=see_link\">",
"     \"Complications of total knee arthroplasty\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/35/15929?source=see_link\">",
"     \"Preoperative evaluation and perioperative management of patients with rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21308429\">",
"    <span class=\"h1\">",
"     FREQUENCY OF JOINT REPLACEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The advent of total joint replacement has been considered to be a major breakthrough and an important therapeutic option in the management of RA. A 23-year, prospective, longitudinal, observational study (from a single referral center) of total joint replacement and its predictors in 1600 patients with RA followed between 1974 and 1997 from the time of diagnosis revealed the following [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 25 percent underwent total joint arthroplasty.",
"     </li>",
"     <li>",
"      For patients with one total joint arthroplasty, 25 percent required an additional arthroplasty within one year, and 50 percent required an additional arthroplasty within seven years.",
"     </li>",
"     <li>",
"      Ten years after total joint replacement, approximately 6 percent of implanted knees and 4 percent of implanted hips had been replaced with a second arthroplasty.",
"     </li>",
"     <li>",
"      The risk of requiring a total joint replacement increased by threefold to sixfold with highly abnormal values obtained with any of the following: the Health Assessment Disability scale, global severity of disease assessment, and measurement of the erythrocyte sedimentation rate (ESR).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Subsequent studies revealed similar results [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. A 2010 study showed that the rates of joint surgery in patients with RA have declined since reaching the peak in the 1990s [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/4\">",
"     4",
"    </a>",
"    ]. Among younger patients with RA, aged 40 to 59, the rates of knee and hip surgery decreased by 19 and 40 percent, respectively. However these rates increased in patients older than 60 years. These results may reflect the beneficial effect of changes in antirheumatic treatments, with an expected lag in older patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS AND SURGICAL OPTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;When medical therapy fails to control RA in a specific joint or joints, one should consider reconstructive surgery, depending upon the joint in question. The main indications for surgery are intractable joint pain (with activity or at rest) and the presence of an unacceptable functional decline. Pain or functional declines are ascribed to joint destruction. This must be accompanied by failure of all of the nonsurgical approaches to the management of the arthritis including a change in disease-modifying, immunosuppressive, or biologic drug regimens, the use of more potent analgesics, and rehabilitation therapies. Plain radiographs should be obtained to confirm the end-stage nature of the arthritis. In addition, bursitis, tendinitis, and nerve entrapment syndromes must be excluded as causes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42472?source=see_link\">",
"     \"Overview of soft tissue rheumatic disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The goal of surgery in the management of RA is the relief of pain and the restoration of joint function. When clinically indicated, surgery is recommended to take place in a timely manner because a prolonged delay can lead to fixed deformities, soft tissue contractures, or excessive muscle atrophy, which prevents a good postoperative recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgical options for the patient with RA include the following procedures:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tenosynovectomy to excise inflamed tendon sheaths or to repair a recent tendon rupture (eg, hand tendons)",
"     </li>",
"     <li>",
"      Arthroscopic repair of tendon rupture (eg, rotator cuff)",
"     </li>",
"     <li>",
"      Arthroscopic or open synovectomy to excise inflamed synovium in an attempt to reduce pain, to temporarily prevent cartilage destruction, or to remove joint debris that impinges upon normal joint range of motion (any large joint). These operations have become much less common with the development of more effective medical treatment approaches since the 1990s.",
"     </li>",
"     <li>",
"      Osteotomy to realign weightbearing bones to correct valgus or varus deformities of the knee",
"     </li>",
"     <li>",
"      Joint fusion to stabilize destroyed joints that are not easily replaced (eg, ankle, wrist, thumb, and cervical spine)",
"     </li>",
"     <li>",
"      Soft tissue release to correct severe contractures that develop around joints with attendant marked loss of motion. This was more commonly seen in the past when there were many severely debilitated and bedridden RA patients.",
"     </li>",
"     <li>",
"      Small joint implant arthroplasty (eg, metacarpophalangeal joints) to reduce pain and to improve hand function",
"     </li>",
"     <li>",
"      Metatarsal head excision arthroplasties to alleviate severe forefoot pain and to improve gait",
"     </li>",
"     <li>",
"      Total joint replacement (eg, shoulder, elbow, wrist, hip, knee, ankle), which will be the focus of the remainder of this topic review",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major contraindication to joint replacement is active systemic or articular infection. Improvements in the perioperative management of patients have markedly reduced the risk associated with comorbid medical conditions, such as hypertension, cardiovascular disease, diabetes, obesity, or bleeding disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TOTAL JOINT ARTHROPLASTY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Preoperative evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative evaluation for patients with rheumatic diseases is presented in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/35/15929?source=see_link\">",
"     \"Preoperative evaluation and perioperative management of patients with rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cervical spine &mdash; In addition to the usual preoperative screening for surgical clearance, the patient with RA needs to be evaluated for cervical spine instability. Flexion and extension radiographs of cervical spine showing an increased anterior atlantodental interval (ADI) of greater than 3 mm or a posterior atlantodental interval of less than 14 mm suggest severe cervical spine subluxation and instability [",
"      <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/6\">",
"       6",
"      </a>",
"      ]. These patients are at risk for cord impingement and neurologic compromise as a result of the perioperative manipulations that occur with surgery; as a result, general anesthesia and controlled intubation should be approached with caution. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41080?source=see_link\">",
"       \"Cervical subluxation in rheumatoid arthritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Autologous blood transfusion &mdash; Postoperative blood transfusions are sometimes required for large joint replacements such as the shoulder, hip, and knee. Preoperative autologous blood donation is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12134?source=see_link\">",
"       \"Preoperative autologous blood donation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Minimizing risk of prosthetic joint infection &mdash; Infectious complications associated with joint implant surgery remain a serious concern in the patient with RA. Potential sources for infection, such as dental caries, skin lesions, and urinary tract infections, should be screened for and treated to prevent future hematogenous spread of these infections to prosthetic joints [",
"      <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]. In a prospective study of all total joint replacement (TJR) surgeries from the Norwegian arthroplasty register, a 1.6-times higher risk of total knee replacement (TKR) revision surgery due to infection was found in RA patients compared with OA patients. No increase in the risk of total hip replacement (THR) revision surgery due to infection was found in RA patients compared with OA patients in the first five postoperative years. A higher incidence of late infection after six years was noted in both THR and TKR patients with RA [",
"      <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Management of antirheumatic drug therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of antirheumatic drug therapy in the perioperative period, including the risk of suppression of the hypothalamic-pituitary-adrenal axis due to glucocorticoid use, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/35/15929?source=see_link&amp;anchor=H6#H6\">",
"     \"Preoperative evaluation and perioperative management of patients with rheumatic diseases\", section on 'Medication management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/35/15929?source=see_link&amp;anchor=H13#H13\">",
"     \"Preoperative evaluation and perioperative management of patients with rheumatic diseases\", section on 'Rheumatoid arthritis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Surgical priorities",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the patient with RA has multiple joints in need of surgical attention, establishing the proper surgical sequence is an important issue. Lower extremity surgery should generally predate upper extremity surgery, when possible [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/10\">",
"     10",
"    </a>",
"    ]. In the upper extremity, wrist deformities should be corrected before hand surgery in order to maintain distal stability and alignment. Whether elbow or shoulder replacement should precede wrist and hand surgery is controversial and should be decided on an individual basis [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the lower extremity, foot and ankle surgery should be performed before hip and knee replacement in order to provide stability for lower extremity rehabilitation [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/11\">",
"     11",
"    </a>",
"    ]. However, if knee malalignment is particularly severe, this must be addressed first. In general, ankle and hindfoot procedures should be performed before forefoot reconstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/11\">",
"     11",
"    </a>",
"    ]. Unless there is severe pain, instability, or contracture of the knee joint, arthroplasty of the ipsilateral destroyed hip should be performed prior to knee reconstruction, because hip rehabilitation generally requires less functional range of motion of the ipsilateral knee than knee rehabilitation requires of the hip.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Total hip arthroplasty",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total hip replacement (THR) has become one of the most frequently performed reconstructive surgical procedures in orthopedic surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10106?source=see_link\">",
"     \"Total hip arthroplasty\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The success rate has improved markedly since John Charnley popularized the technique in the late 1950s [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/13\">",
"     13",
"    </a>",
"    ]. Factors influencing the surgical outcome include patient age, general health, and preoperative functional status. At 10 to 20 years of follow-up, a 90 percent success rate can be predicted for the average patient undergoing a cemented total hip arthroplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Sixty to 90 percent of total hip replacements in the US utilize cementless designs and, at 10-year follow-up, have a 95 percent rate of prosthesis survival, with some maintaining this success rate at 20-year follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/16\">",
"     16",
"    </a>",
"    ]. Since the advent of more effective medical treatments for RA, the incidence of THR for young adults with RA has diminished substantially; less than 10 percent of THR surgeries in young adults are performed for inflammatory arthropathies. The majority of THR surgeries in patients under 30 years of age are for osteonecrosis or secondary osteoarthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/17\">",
"     17",
"    </a>",
"    ]. Outcome studies have indicated that the failure rate of cementless implants is primarily in the acetabular component and was less than 7 percent with a follow-up of 4 to 16 years, with the exception of one study with a failure rate of 49 percent attributed to an unsuccessful acetabular hydroxyapatite coating.",
"   </p>",
"   <p>",
"    An important operative decision is whether to implant the hip with or without cement. Cemented fixation techniques have been used since Charnley introduced them, but their use became widespread in the 1970s. Cementless components were introduced in the late 1980s. A cementless component is generally advised for the young patient and for anyone with good bone stock, and a cemented implant is generally preferred for the older, low-demand patient with thinner bone stock. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10106?source=see_link\">",
"     \"Total hip arthroplasty\"",
"    </a>",
"    .) Patients can apply weight on a cemented hip prosthesis within a few days following surgery, while they may have to wait for weeks before applying weight to a cementless prosthesis. A disadvantage of cemented hip prostheses is the higher risk of prosthesis loosening, particularly in patients with RA [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of infection in primary total hip arthroplasty varies from 0.4 to 1.5 percent. In a prospective study of all THRs from the Norwegian arthroplasty registry, no increase in the risk of THR revision surgery due to infection was found in RA patients compared with OA patients in the first five postoperative years, but a higher rate of late infection after six years was noted [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/9\">",
"     9",
"    </a>",
"    ]. The pathogenesis, clinical manifestations, treatment, and prevention of prosthetic joint infections are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42680?source=see_link\">",
"     \"Clinical manifestations and diagnosis of prosthetic joint infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/19/6457?source=see_link\">",
"     \"Treatment of prosthetic joint infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28198?source=see_link\">",
"     \"Prevention of prosthetic joint infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Total knee arthroplasty",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported success rate for total knee arthroplasty is in excess of 85 percent at 10 years in patients with RA [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. The indications, preoperative evaluation, selection of components and of fixation technique, perioperative management, and outcomes of total knee arthroplasty (knee replacement) are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/6/17514?source=see_link\">",
"     \"Total knee arthroplasty\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Revision rates due to septic or aseptic loosening are low. Problems with the patellofemoral articulation, including patellar instability, loosening, fracture, and component failure, are a leading cause of the need for total knee arthroplasty reoperation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/32/16902?source=see_link&amp;anchor=H10#H10\">",
"     \"Complications of total knee arthroplasty\", section on 'Patellofemoral disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a prospective study of all TKRs from the Norwegian arthroplasty register, a 1.6-fold higher risk of TKR revision surgery due to infection was found in RA patients compared with OA patients [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/9\">",
"     9",
"    </a>",
"    ]. Removal and delayed replacement of the knee prosthesis may result in the best functional results. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/32/16902?source=see_link&amp;anchor=H6#H6\">",
"     \"Complications of total knee arthroplasty\", section on 'Infection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is unclear whether the use of continuous passive motion devices in the postoperative management of total knee arthroplasty results in enough clinical benefit to justify the inconvenience and expense of the procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/6/17514?source=see_link&amp;anchor=H36#H36\">",
"     \"Total knee arthroplasty\", section on 'Postoperative management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Total shoulder arthroplasty",
"    </span>",
"    &nbsp;&mdash;&nbsp;Success rate for total shoulder replacement using the Neer prosthesis is similar to that of total hip or knee replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/22\">",
"     22",
"    </a>",
"    ]. Introduced in 1951, it became the procedure of choice for replacement of the RA shoulder because it was the most reliable method for eliminating refractory pain [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. The Neer arthroplasty is associated with a higher failure rate in patients with RA under the age of 50 [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/22\">",
"     22",
"    </a>",
"    ]. There have been many types of shoulder arthroplasty prostheses developed subsequently, in attempts to improve upon the Neer prosthesis, with varying degrees of success [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Preoperative evaluation of the shoulder using magnetic resonance imaging (MRI) or computed tomographic (CT) arthrography is usually recommended to evaluate the extent of rotator cuff disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35961?source=see_link\">",
"     \"Evaluation of the patient with shoulder complaints\"",
"    </a>",
"    .) However, rotator cuff deficiency is no longer considered an absolute contraindication to total shoulder arthroplasty (TSA). Most patients with RA have some degree of rotator cuff tear, and 20 to 35 percent have full thickness tears [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/26\">",
"     26",
"    </a>",
"    ]. In one study of 195 total shoulder arthroplasties and 95 hemiarthroplasties in 247 RA patients, comparing results in patients with or without an intact rotator cuff, there was comparable pain relief in both groups. However, the risk of revision surgery was significantly less, and the range of motion and degree of pain relief were significantly better, in the patients who received TSA if they had an intact rotator cuff [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Joint arthroplasty and concomitant rotator cuff repair can be performed together, although the results are less desirable. Early intervention at an optimum time when there is minimal destruction of the soft tissues surrounding the shoulder is of utmost importance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Total elbow arthroplasty",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain is the main indication for total elbow arthroplasty. Pain relief following total elbow replacement is excellent in most patients with RA. In some younger patients, excision of the radial head and synovectomy of the elbow have offered a conservative and effective method of treatment for refractory elbow pain. However, subsequent conversion of this procedure to a standard capitellocondylar total elbow replacement is more difficult. In one series, the degree of improvement in such patients was lower than in those who underwent primary elbow arthroplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/28\">",
"     28",
"    </a>",
"    ]. In RA patients with radiographic evidence of advanced joint destruction and with pain, stiffness, and instability that limits activities, implant arthroplasty is preferred to radial head excision with synovectomy. Since 1975, more than 20 elbow protheses have been developed, but comparison of results is difficult because of the small numbers of patients reported and because of the lack of standardized assessment. Rating systems have been established which are enabling more standardized comparison of prosthesis design [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/25,29,30\">",
"     25,29,30",
"    </a>",
"    ]. Two types of total elbow arthroplasties are frequently chosen by orthopedists. One is a semiconstrained metal-to-polyethylene hinge; the other is an unconstrained capitellocondylar design [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Overall, pain relief is successful in more than 90 percent of patients, and long-term complication rates are approximately 11 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/31\">",
"     31",
"    </a>",
"    ]. Though infection has historically been the main complication in elbow replacements, further development in surgical techniques has reduced the incidence of infection to less than 3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/31\">",
"     31",
"    </a>",
"    ]. Loosening of the implant remains a concern [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/32\">",
"     32",
"    </a>",
"    ]. Patients who have had previous elbow infections or a history of heterotopic ossification should be advised to avoid total elbow arthroplasty, if possible [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Total wrist arthroplasty",
"    </span>",
"    &nbsp;&mdash;&nbsp;The wrist joint is the key to stability of the hand that leads to normal function. Recurrence of ulnar deviation at the metacarpophalangeal joint almost always occurs unless wrist stabilization is first obtained [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/33\">",
"     33",
"    </a>",
"    ]. Until the 1970s, wrist arthrodesis (fusion) was the only commonly employed surgical procedure to relieve pain and to provide stability to this joint. Limited or total wrist arthrodesis continues to be performed depending upon the degree",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    location of joint damage.",
"   </p>",
"   <p>",
"    Total wrist arthroplasty (TWA) is another surgical option. However, its use has been limited due to the high incidence of complications, including loosening, infection, subsidence, and dislocations. Complications have been reported in 40 percent of patients with the Voltz implant [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. A 2008 systematic review of 18 total wrist arthroplasty studies that included 500 procedures compared the outcomes of TWA with total wrist arthrodesis for RA [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/37\">",
"     37",
"    </a>",
"    ]. Outcomes for total wrist arthrodesis were at least comparable and possibly better than those for TWA. Fusion provided pain relief in 98 percent of the cases compared with 90 percent for arthroplasty, and only 3 out of 14 studies with appropriate data showed an average active arc of wrist motion within the functional range for patients undergoing arthroplasty. Patient satisfaction was comparable and was reported as more than 90 percent in each group. There were more major complications in the arthroplasty group, and 21 percent underwent revision surgery, including prosthesis removal without replacement or salvage arthrodesis in 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Total ankle arthroplasty",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ankle arthrodesis has been the treatment of choice for relief of severe ankle and hindfoot pain in patients with RA [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. In one series of 24 ankles followed for an average of five years, 19 were associated with no pain, and four were associated with only mild, occasional pain [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ankle arthroplasty has been offered as an alternative surgical option. One study of 27 patients followed for up to 14 years noted good results overall, but five patients (19 percent) required later surgical revision or ankle arthrodesis [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/40\">",
"     40",
"    </a>",
"    ]. A study of second-generation ankle prostheses showed reliable pain relief and good functional results with 88.5 percent of implants remaining stable at a mean intermediate follow-up of 6.3 years [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 2005 systematic review of interventions for foot disease in RA noted that there had been no randomized controlled trials of surgery for RA foot disease [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/42\">",
"     42",
"    </a>",
"    ]. The evidence so far comes from observational studies alone, and further evidence will be needed before clear guidelines for the use of ankle arthroplasty in RA can be developed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Total metacarpophalangeal arthroplasty",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2005 review of the studies reporting results of hand surgery in RA concluded that the available studies do not allow for a clear definition of surgical indications or criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/43\">",
"     43",
"    </a>",
"    ]. This view was shared by authors of another review of hand surgery in RA patients across the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/44\">",
"     44",
"    </a>",
"    ]; these investigators found large variations in the surgical management of the rheumatoid hand that depended upon geographic location. Rheumatologists and hand surgeons often disagree about the indications for RA hand procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/12,45\">",
"     12,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Outcomes involving surgery of the metacarpal phalangeal (MCP) joints have traditionally been measured by range of motion restored, by patient satisfaction, by subjective functional outcome, and by complication rate. The MCP joints, which are critical for the positioning and functioning of the digits, are condylar joints. Thus, they are less stable than the proximal interphalangeal (PIP) joints.",
"   </p>",
"   <p>",
"    The final outcome with implant arthroplasty is never a normal functioning articulation; rather, the result is a painless arthroplasty with a useful arc of motion [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/46\">",
"     46",
"    </a>",
"    ]. Benefits usually include an arc of motion in the 40 to 50 degree range, improvement of extensor lag, and correction of ulnar deviation to 0 to 20 degrees [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A prospective, multicenter, cohort study of 46 RA patients followed two years after reconstructive surgery found objective improvement in MCP arc of motion, ulnar drift, and extension lag that correlated well with patient satisfaction scores as measured by the Michigan Hand Questionnaire (MHQ), despite the fact that there were minimal improvements in grip and pinch strength [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/49\">",
"     49",
"    </a>",
"    ]. A 2000 systematic review concluded that silicone implant arthroplasty was beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with excellent PIP joints tend to gain less flexion of their MCP joints with surgery; in this setting, special attention is, therefore, undertaken during rehabilitation to improve MCP function [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Possible complications with implant arthroplasty include recurrence of ulnar deviation, loss of the MCP&rsquo;s arc of flexion, infection, and implant breakage [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/51\">",
"     51",
"    </a>",
"    ]. A broken prosthesis does not necessarily require surgical replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The safety and reliability of total joint arthroplasty have improved markedly since the initial use of these procedures. However, there are a number of potential complications, the most important of which are infection, thromboembolic disease, and implant loosening. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/39/1658?source=see_link\">",
"     \"Complications of total hip arthroplasty\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although there have been rare case reports of sarcomas of bone or soft tissue adjacent to prosthetic joints, a large and long-term epidemiologic study of cancer rates among nearly 117,000 such patients, followed for a mean of seven years, found no increase in the overall risk of cancer or sarcoma [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periprosthetic joint infection is a serious complication of hip and knee replacement surgery with a prevalence of 1 to 3 percent and is a major reason for hip and knee revision surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/54-57\">",
"     54-57",
"    </a>",
"    ]. Patients with RA appear to be at higher risk for infection after total knee arthroplasty and, possibly, after total hip arthroplasty, compared with patients with osteoarthritis (OA) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/58\">",
"     58",
"    </a>",
"    ]. It is most likely that the largest shares of this risk are related to the underlying disease (RA) as well as its associated comorbidities. The epidemiology, clinical manifestations, microbiology, and diagnosis of prosthetic joint infections are reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42680?source=see_link\">",
"     \"Clinical manifestations and diagnosis of prosthetic joint infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ESR and C-reactive protein (CRP), which may be helpful in identifying postoperative infections in patients with noninflammatory causes of joint replacement, may not be helpful in patients with active RA. All culture specimens obtained should be sent for aerobic, anaerobic, fungal, and acid fast organism cultures, since patients with RA may be immunocompromised from RA as well as from their preoperative medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Thromboembolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of venous thromboembolism (VTE), which includes deep venous thrombosis (DVT)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pulmonary embolism (PE), has steadily declined since 1990, with the adoption of less invasive surgical techniques and of earlier postoperative mobilization and discharge. VTE still remains a significant cause of morbidity and potential mortality, although VTE-related deaths in patients undergoing orthopedic surgical procedures were infrequently reported in trials since 2003 [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/59\">",
"     59",
"    </a>",
"    ]. The 2012 American College of Chest Physicians guideline estimated that the risk of nonfatal, symptomatic VTE rate was reduced from 4.3 to 1.8 percent in the month after major orthopedic surgery when low molecular weight",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (LMWH) was utilized perioperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/59\">",
"     59",
"    </a>",
"    ]. A number of other alternative agents may also be utilized. The prevention of venous thromboembolism in orthopedic surgical patients, including those undergoing joint arthroplasty, is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=see_link\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link\">",
"     \"Therapeutic use of warfarin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/23/44408?source=see_link\">",
"     \"Therapeutic use of fondaparinux\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/59/43961?source=see_link\">",
"     \"Low molecular weight heparin for venous thromboembolic disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Implant loosening and failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Implant loosening, which typically presents with pain, is the major cause of implant failure. Loosening may occur due to infection, to mechanical failure related to surgical technique, or to osteolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Infection'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Osteolysis results when particulate polyethylene debris released from worn implants causes a cellular immune response that forms a synovial-like membrane around the prosthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/61\">",
"     61",
"    </a>",
"    ], and this has been reported in several designs of cemented and cementless implants [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/62\">",
"     62",
"    </a>",
"    ]. Increased cellular proliferation to both acrylic and cobalt-chromium has been observed in patients with aseptically loosened metal-on-metal and ceramic-on-ceramic prostheses [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/63\">",
"     63",
"    </a>",
"    ]. Metal-on-metal implants have been shown to fail at a significantly higher rate than ceramic-on-ceramic or metal-on-polyethylene implants, and a number of concerns have arisen regarding the use of these prostheses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/39/1658?source=see_link&amp;anchor=H14353540#H14353540\">",
"     \"Complications of total hip arthroplasty\", section on 'Metal-on-metal bearing surfaces'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early detection of implant loosening is required for successful revision and prevention of catastrophic implant failure. The diagnosis of hip implant loosening is often confirmed if there is a radiolucent zone of 2 mm or more in width in a patient who has pain on weightbearing that is relieved by rest. Conventional radiography is the mainstay for evaluating these joints, with CT scanning and scintigraphy playing smaller roles [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/64\">",
"     64",
"    </a>",
"    ]. Another technique is digital subtraction arthrography, which may be useful if conventional x-rays are normal. When used to evaluate the femoral component in 78 painful hip prostheses, this technique had 96 percent sensitivity and 100 percent specificity for the diagnosis of component loosening [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H804745\">",
"    <span class=\"h2\">",
"     Hip dislocation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with RA may be at higher risk of hip dislocation as a complication of total hip arthroplasty compared with patients with OA. A systematic review of 40 studies included a meta-analysis of four studies that analyzed the results of surgery in 1637 patients with RA and in 61,810 patients with OA, which found a significantly higher risk of hip dislocation in the RA patients (OR 2.16, 95% CI 1.52-3.07) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/20/32073/abstract/58\">",
"     58",
"    </a>",
"    ]. Estimates of absolute risk of hip dislocation with THR vary but are generally between &lt;1 and 2 percent. Different surgical approaches and techniques may have an impact on the degree of risk; a careful discussion about such particular risks should take place between surgeon and patient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/39/1658?source=see_link&amp;anchor=H20#H20\">",
"     \"Complications of total hip arthroplasty\", section on 'Dislocation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?28/50/29474?source=see_link\">",
"       \"Patient information: Knee replacement (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/34/23075?source=see_link\">",
"       \"Patient information: Hip replacement (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/13/21717?source=see_link\">",
"       \"Patient information: Total knee replacement (arthroplasty) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/30/21987?source=see_link\">",
"       \"Patient information: Total hip replacement (arthroplasty) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H256304326\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The main indication for joint replacement surgery in patients with rheumatoid arthritis (RA) is joint destruction, despite medical and rehabilitative therapy, which has resulted in intractable joint pain (with activity or at rest) or in an unacceptable functional decline. Other causes of articular and periarticular pain should be excluded. The goal of surgery in RA is the relief of pain and the restoration of joint function. Once a determination has been made that surgery is clinically indicated, it should take place in a timely manner to avoid fixed deformities, soft tissue contractures, or excessive muscle atrophy, which prevent a good postoperative recovery. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications and surgical options'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The only major contraindication to joint replacement is active systemic or articular infection. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Particular attention should be given to the preoperative evaluation, including identification of patients with cervical spine instability, who are at increased risk of neurologic complications, and to the identification of potential sources for infection, such as dental caries, skin lesions, and urinary tract infections, for which the patient should be screened and treated to prevent future hematogenous spread of these infections to prosthetic joints. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Preoperative evaluation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/35/15929?source=see_link\">",
"       \"Preoperative evaluation and perioperative management of patients with rheumatic diseases\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The dosing of certain drugs used in the treatment of RA may need to be adjusted to minimize perioperative and postoperative complications. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Management of antirheumatic drug therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When the patient with RA has multiple joints in need of surgical attention, establishing the proper surgical sequence is an important issue, which depends upon the specific joints involved and upon the need to optimize stability, alignment, and rehabilitative potential. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Surgical priorities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The specific evaluation and outcomes can differ between joints. Hip and knee arthroplasties generally have a high level of success. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Total hip arthroplasty'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Total knee arthroplasty'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Total shoulder arthroplasty'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Total elbow arthroplasty'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Total wrist arthroplasty'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Total ankle arthroplasty'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Total metacarpophalangeal arthroplasty'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most important of the potential complications of joint replacement in RA include infection, thromboembolic disease, and implant loosening. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Complications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Infection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Thromboembolism'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23\">",
"       'Implant loosening and failure'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/1\">",
"      Wolfe F, Zwillich SH. The long-term outcomes of rheumatoid arthritis: a 23-year prospective, longitudinal study of total joint replacement and its predictors in 1,600 patients with rheumatoid arthritis. Arthritis Rheum 1998; 41:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/2\">",
"      Massardo L, Gabriel SE, Crowson CS, et al. A population based assessment of the use of orthopedic surgery in patients with rheumatoid arthritis. J Rheumatol 2002; 29:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/3\">",
"      Kapetanovic MC, Lindqvist E, Saxne T, Eberhardt K. Orthopaedic surgery in patients with rheumatoid arthritis over 20 years: prevalence and predictive factors of large joint replacement. Ann Rheum Dis 2008; 67:1412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/4\">",
"      Louie GH, Ward MM. Changes in the rates of joint surgery among patients with rheumatoid arthritis in California, 1983-2007. Ann Rheum Dis 2010; 69:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/5\">",
"      Ballard WT, Buckwalter WT. Operative treatment of rheumatic disease. Primer on Rheumatic Diseases 1997; 11:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/6\">",
"      Grauer JN, Tingstad EM, Rand N, et al. Predictors of paralysis in the rheumatoid cervical spine in patients undergoing total joint arthroplasty. J Bone Joint Surg Am 2004; 86-A:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/7\">",
"      Luessenhop CP, Higgins LD, Brause BD, Ranawat CS. Multiple prosthetic infections after total joint arthroplasty. Risk factor analysis. J Arthroplasty 1996; 11:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/8\">",
"      Poss R, Thornhill TS, Ewald FC, et al. Factors influencing the incidence and outcome of infection following total joint arthroplasty. Clin Orthop Relat Res 1984; :117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/9\">",
"      Schrama JC, Espehaug B, Hallan G, et al. Risk of revision for infection in primary total hip and knee arthroplasty in patients with rheumatoid arthritis compared with osteoarthritis: a prospective, population-based study on 108,786 hip and knee joint arthroplasties from the Norwegian Arthroplasty Register. Arthritis Care Res (Hoboken) 2010; 62:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/10\">",
"      Goodman SM, Figgie MP, Mackenzie CR. Perioperative management of patients with connective tissue disease. HSS J 2011; 7:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/11\">",
"      Dunbar RP, Alexiades MM. Decision making in rheumatoid arthritis. Determining surgical priorities. Rheum Dis Clin North Am 1998; 24:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/12\">",
"      Moran SL, Bishop AT. Clinical update: surgical management of rheumatoid hand. Lancet 2007; 370:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/13\">",
"      Charnley J. Arthroplasty of the hip. A new operation. Lancet 1961; 1:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/14\">",
"      Cornell CN, Ranawat CS. The impact of modern cement techniques on acetabular fixation in cemented total hip replacement. J Arthroplasty 1986; 1:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/15\">",
"      Ranawat CS. Surgical management of the rheumatoid hip. Rheum Dis Clin North Am 1998; 24:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/16\">",
"      Pivec R, Johnson AJ, Mears SC, Mont MA. Hip arthroplasty. Lancet 2012; 380:1768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/17\">",
"      Polkowski GG, Callaghan JJ, Mont MA, Clohisy JC. Total hip arthroplasty in the very young patient. J Am Acad Orthop Surg 2012; 20:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/18\">",
"      Creighton MG, Callaghan JJ, Olejniczak JP, Johnston RC. Total hip arthroplasty with cement in patients who have rheumatoid arthritis. A minimum ten-year follow-up study. J Bone Joint Surg Am 1998; 80:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/19\">",
"      Chmell MJ, Scott RD. Total knee arthroplasty in patients with rheumatoid arthritis. An overview. Clin Orthop Relat Res 1999; :54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/20\">",
"      Schai PA, Scott RD, Thornhill TS. Total knee arthroplasty with posterior cruciate retention in patients with rheumatoid arthritis. Clin Orthop Relat Res 1999; :96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/21\">",
"      Schai PA, Thornhill TS, Scott RD. Total knee arthroplasty with the PFC system. Results at a minimum of ten years and survivorship analysis. J Bone Joint Surg Br 1998; 80:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/22\">",
"      Sperling JW, Cofield RH, Rowland CM. Neer hemiarthroplasty and Neer total shoulder arthroplasty in patients fifty years old or less. Long-term results. J Bone Joint Surg Am 1998; 80:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/23\">",
"      Stewart MP, Kelly IG. Total shoulder replacement in rheumatoid disease: 7- to 13-year follow-up of 37 joints. J Bone Joint Surg Br 1997; 79:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/24\">",
"      Wakitani S, Imoto K, Saito M, et al. Evaluation of surgeries for rheumatoid shoulder based on the destruction pattern. J Rheumatol 1999; 26:41.",
"     </a>",
"    </li>",
"    <li>",
"     Canale ST, Beaty JH. Campbell's Operative Orthopaedics, 11th, Mosby, 2007. p.483.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/26\">",
"      Curran JF, Ellman MH, Brown NL. Rheumatologic aspects of painful conditions affecting the shoulder. Clin Orthop Relat Res 1983; :27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/27\">",
"      Sperling JW, Cofield RH, Schleck CD, Harmsen WS. Total shoulder arthroplasty versus hemiarthroplasty for rheumatoid arthritis of the shoulder: results of 303 consecutive cases. J Shoulder Elbow Surg 2007; 16:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/28\">",
"      Schemitsch EH, Ewald FC, Thornhill TS. Results of total elbow arthroplasty after excision of the radial head and synovectomy in patients who had rheumatoid arthritis. J Bone Joint Surg Am 1996; 78:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/29\">",
"      Hargreaves D, Emery R. Total elbow replacement in the treatment of rheumatoid disease. Clin Orthop Relat Res 1999; :61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/30\">",
"      Jensen CH, Jacobsen S, Ratchke M, Sonne-Holm S. The GSB III elbow prosthesis in rheumatoid arthritis: a 2- to 9-year follow-up. Acta Orthop 2006; 77:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/31\">",
"      Nestor BJ. Surgical treatment of the rheumatoid elbow. An overview. Rheum Dis Clin North Am 1998; 24:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/32\">",
"      van der Lugt JC, Geskus RB, Rozing PM. Primary Souter-Strathclyde total elbow prosthesis in rheumatoid arthritis. Surgical technique. J Bone Joint Surg Am 2005; 87 Suppl 1:67.",
"     </a>",
"    </li>",
"    <li>",
"     Beckenbaugh RD, Linscheid RL. Arthroplasty in the hand and wrist. In: Operative Hand Surgery, 3rd, Green DP (Ed), Churchill Livingstone, New York 1993. p.143.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/34\">",
"      Bosco JA 3rd, Bynum DK, Bowers WH. Long-term outcome of Volz total wrist arthroplasties. J Arthroplasty 1994; 9:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/35\">",
"      Dennis DA, Ferlic DC, Clayton ML. Volz total wrist arthroplasty in rheumatoid arthritis: a long-term review. J Hand Surg Am 1986; 11:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/36\">",
"      Gellman H, Hontas R, Brumfield RH Jr, et al. Total wrist arthroplasty in rheumatoid arthritis. A long-term clinical review. Clin Orthop Relat Res 1997; :71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/37\">",
"      Cavaliere CM, Chung KC. A systematic review of total wrist arthroplasty compared with total wrist arthrodesis for rheumatoid arthritis. Plast Reconstr Surg 2008; 122:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/38\">",
"      Cracchiolo A 3rd, Cimino WR, Lian G. Arthrodesis of the ankle in patients who have rheumatoid arthritis. J Bone Joint Surg Am 1992; 74:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/39\">",
"      Felix NA, Kitaoka HB. Ankle arthrodesis in patients with rheumatoid arthritis. Clin Orthop Relat Res 1998; :58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/40\">",
"      Kofoed H, S&oslash;rensen TS. Ankle arthroplasty for rheumatoid arthritis and osteoarthritis: prospective long-term study of cemented replacements. J Bone Joint Surg Br 1998; 80:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/41\">",
"      Su EP, Kahn B, Figgie MP. Total ankle replacement in patients with rheumatoid arthritis. Clin Orthop Relat Res 2004; :32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/42\">",
"      Farrow SJ, Kingsley GH, Scott DL. Interventions for foot disease in rheumatoid arthritis: a systematic review. Arthritis Rheum 2005; 53:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/43\">",
"      Ghattas L, Mascella F, Pomponio G. Hand surgery in rheumatoid arthritis: state of the art and suggestions for research. Rheumatology (Oxford) 2005; 44:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/44\">",
"      Alderman AK, Chung KC, Demonner S, et al. The rheumatoid hand: a predictable disease with unpredictable surgical practice patterns. Arthritis Rheum 2002; 47:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/45\">",
"      Alderman AK, Ubel PA, Kim HM, et al. Surgical management of the rheumatoid hand: consensus and controversy among rheumatologists and hand surgeons. J Rheumatol 2003; 30:1464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/46\">",
"      Beckenbaugh RD. Implant arthroplasty in the rheumatoid hand and wrist: current state of the art in the United States. J Hand Surg Am 1983; 8:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/47\">",
"      Gellman H, Stetson W, Brumfield RH Jr, et al. Silastic metacarpophalangeal joint arthroplasty in patients with rheumatoid arthritis. Clin Orthop Relat Res 1997; :16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/48\">",
"      Stirrat CR. Metacarpophalangeal joints in rheumatoid arthritis of the hand. Hand Clin 1996; 12:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/49\">",
"      Waljee JF, Chung KC. Objective functional outcomes and patient satisfaction after silicone metacarpophalangeal arthroplasty for rheumatoid arthritis. J Hand Surg Am 2012; 37:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/50\">",
"      Chung KC, Kowalski CP, Myra Kim H, Kazmers IS. Patient outcomes following Swanson silastic metacarpophalangeal joint arthroplasty in the rheumatoid hand: a systematic overview. J Rheumatol 2000; 27:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/51\">",
"      Blair WF, Shurr DG, Buckwalter JA. Metacarpophalangeal joint implant arthroplasty with a Silastic spacer. J Bone Joint Surg Am 1984; 66:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/52\">",
"      Nalebuff EA. The rheumatoid hand. Reflections on metacarpophalangeal arthroplasty. Clin Orthop Relat Res 1984; :150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/53\">",
"      Signorello LB, Ye W, Fryzek JP, et al. Nationwide study of cancer risk among hip replacement patients in Sweden. J Natl Cancer Inst 2001; 93:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/54\">",
"      Parvizi J, Adeli B, Zmistowski B, et al. Management of periprosthetic joint infection: the current knowledge: AAOS exhibit selection. J Bone Joint Surg Am 2012; 94:e104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/55\">",
"      Vessely MB, Whaley AL, Harmsen WS, et al. The Chitranjan Ranawat Award: Long-term survivorship and failure modes of 1000 cemented condylar total knee arthroplasties. Clin Orthop Relat Res 2006; 452:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/56\">",
"      Fehring TK, Odum S, Griffin WL, et al. Early failures in total knee arthroplasty. Clin Orthop Relat Res 2001; :315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/57\">",
"      Clohisy JC, Calvert G, Tull F, et al. Reasons for revision hip surgery: a retrospective review. Clin Orthop Relat Res 2004; :188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/58\">",
"      Ravi B, Escott B, Shah PS, et al. A systematic review and meta-analysis comparing complications following total joint arthroplasty for rheumatoid arthritis versus for osteoarthritis. Arthritis Rheum 2012; 64:3839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/59\">",
"      Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e278S.",
"     </a>",
"    </li>",
"    <li>",
"     Canale ST, Beaty JH. Campbell's Operative Orthopaedics, 11th, Mosby, 2007. p.420.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/61\">",
"      Toumbis CA, Kronick JL, Wooley PH, Nasser S. Total joint arthroplasty and the immune response. Semin Arthritis Rheum 1997; 27:44.",
"     </a>",
"    </li>",
"    <li>",
"     Canale ST, Beaty JH. Campbell's Operative Orthopaedics, 11th, Mosby, 2007. p.428.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/63\">",
"      Wooley PH, Petersen S, Song Z, Nasser S. Cellular immune responses to orthopaedic implant materials following cemented total joint replacement. J Orthop Res 1997; 15:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/64\">",
"      Allen AM, Ward WG, Haygood TM. Imaging of the total hip arthroplasty. J South Orthop Assoc 1995; 4:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/20/32073/abstract/65\">",
"      Walker CW, FitzRandolph RL, Collins DN, Dalrymple GV. Arthrography of painful hips following arthroplasty: digital versus plain film subtraction. Skeletal Radiol 1991; 20:403.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7478 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-46FA143880-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_20_32073=[""].join("\n");
var outline_f31_20_32073=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H256304326\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21308429\">",
"      FREQUENCY OF JOINT REPLACEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS AND SURGICAL OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TOTAL JOINT ARTHROPLASTY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Preoperative evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Management of antirheumatic drug therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Surgical priorities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Total hip arthroplasty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Total knee arthroplasty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Total shoulder arthroplasty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Total elbow arthroplasty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Total wrist arthroplasty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Total ankle arthroplasty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Total metacarpophalangeal arthroplasty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Implant loosening and failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H804745\">",
"      Hip dislocation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H256304326\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41080?source=related_link\">",
"      Cervical subluxation in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42680?source=related_link\">",
"      Clinical manifestations and diagnosis of prosthetic joint infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/39/1658?source=related_link\">",
"      Complications of total hip arthroplasty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/32/16902?source=related_link\">",
"      Complications of total knee arthroplasty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37861?source=related_link\">",
"      Evaluation and medical management of end-stage rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35961?source=related_link\">",
"      Evaluation of the patient with shoulder complaints",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=related_link\">",
"      General principles of management of rheumatoid arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/59/43961?source=related_link\">",
"      Low molecular weight heparin for venous thromboembolic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42472?source=related_link\">",
"      Overview of soft tissue rheumatic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/34/23075?source=related_link\">",
"      Patient information: Hip replacement (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/50/29474?source=related_link\">",
"      Patient information: Knee replacement (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/30/21987?source=related_link\">",
"      Patient information: Total hip replacement (arthroplasty) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/13/21717?source=related_link\">",
"      Patient information: Total knee replacement (arthroplasty) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12134?source=related_link\">",
"      Preoperative autologous blood donation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/35/15929?source=related_link\">",
"      Preoperative evaluation and perioperative management of patients with rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28198?source=related_link\">",
"      Prevention of prosthetic joint infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/23/44408?source=related_link\">",
"      Therapeutic use of fondaparinux",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=related_link\">",
"      Therapeutic use of heparin and low molecular weight heparin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=related_link\">",
"      Therapeutic use of warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10106?source=related_link\">",
"      Total hip arthroplasty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/6/17514?source=related_link\">",
"      Total knee arthroplasty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/19/6457?source=related_link\">",
"      Treatment of prosthetic joint infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_20_32074="Atypical Spitz histo 2";
var content_f31_20_32074=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87141&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87141&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Histologic features of atypical Spitz tumor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In this Spitz tumor with atypical features, the lesion is dome-shaped and circumscribed with a symmetric profile.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_20_32074=[""].join("\n");
var outline_f31_20_32074=null;
var title_f31_20_32075="Proposed classifications";
var content_f31_20_32075=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F75173&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F75173&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Proposed classification for male dyspareunia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        I. Isolated ejaculatory pain (pain during or after ejaculation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        a. Identifiable cause",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        b. Idiopathic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        II. Chronic prostatitis/chronic pelvic pain syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        III. Medical causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        a. Peyronie's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        b. Phimosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        c. Frenulum breve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        d. Hernia repair",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        e. Entrapment of pudendal nerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        f. Infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        g. Interstitial cystitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        IV. Other causes of sexual pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        a. Psychological",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        b. Anodysparuenia in men who have sex with men",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        c. Medications",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Luizzi, GI, Law, A. A guide to sexual pain in men. Practitioner 2005; 249:73.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_20_32075=[""].join("\n");
var outline_f31_20_32075=null;
var title_f31_20_32076="Lab tests in polyneuropathy";
var content_f31_20_32076=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F64055&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F64055&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic tests in polyneuropathy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Predominantly axonal pathophysiology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Initial tests:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Serum glucose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Serum protein immunofixation electrophoresis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vitamin B12 level",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anti-nuclear antibody",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Erythrocyte sedimentation rate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rapid plasma reagin (RPR)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Glycohemoglobin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Additional testing, if history suggestive:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        HIV serology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Urine/blood for heavy metals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Urine/blood for porphyrins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rheumatoid factor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sj&ouml;gren's syndrome testing (Anti-Ro, Anti-La Antibodies)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lyme testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Methylmalonic acid and homocysteine levels (in patients with borderline low serum B12 levels)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hepatitis screen (for types B and C)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Predominantly demyelinating pathophysiology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Initial tests:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Serum protein electrophoresis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Immunoelectrophoresis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Urine protein electrophoresis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hepatitis screen (for types B and C)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lumbar puncture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Additional testing, if history suggestive:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Antimyelin associated glycoprotein (MAG) testing (in patients with predominantly sensory symptoms)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anti-GM1 test (in patients with predominantly motor symptoms)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        HIV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Genetic testing for Charcot-Marie-Tooth Disease; generally, the electrophysiology is also suggestive of a hereditary condition",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_20_32076=[""].join("\n");
var outline_f31_20_32076=null;
var title_f31_20_32077="Survival advanced MF";
var content_f31_20_32077=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F74471&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F74471&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    Mycosis fungoides: Impact of extracutaneous disease on survival",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 500px; height: 283px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Actuarial survival of 600 patients with MF managed at Stanford University calculated from the date of referral. 1: 543 patients with disease apparently limited to the skin (clinical stages I/II/III); 2: 57 patients with extracutaneous disease (clinical stage IV) at the time of presentation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission by Kim, YH, Hoppe, RT. Mycosis fungoides and S&eacute;zary Syndrome. Semin Oncol 1999; 26:276. figure 2, page 280.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_20_32077=[""].join("\n");
var outline_f31_20_32077=null;
var title_f31_20_32078="Evaluation for laxative abuse";
var content_f31_20_32078=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F58754&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F58754&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Evaluation of suspected laxative abuse",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 390px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_20_32078=[""].join("\n");
var outline_f31_20_32078=null;
var title_f31_20_32079="Adult TB case 1 PA view";
var content_f31_20_32079=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F74846&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F74846&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Classic adult type TB PA",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph, PA view, of an 18 year-old high school student exposed 4 years earlier to an infectious pulmonary tuberculosis patient. She was noncompliant with isoniazid prophylaxis. She now presents with cough for one month, fever and night sweats. PA radiograph shows right upper lobe apical and posterior segment infiltrate with cavitation. This radiograph is \"classic\" for adult-type, reactivation tuberculosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John Bernardo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_20_32079=[""].join("\n");
var outline_f31_20_32079=null;
